Simultaneous spatio-temporal measurement of gene expression and cellular activity

ABSTRACT

Provided herein are methods for simultaneous spatio-temporal measurement of gene expression and cellular activity.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Patent ApplicationNo. 63/029,121, filed May 22, 2020 and U.S. Provisional PatentApplication No. 63/044,028, filed Jun. 25, 2020. The entire contents ofthe foregoing applications are incorporated herein by reference.

BACKGROUND

Cells within a tissue of a subject have differences in cell morphologyand/or function due to varied analyte levels (e.g., gene and/or proteinexpression) within the different cells. The specific position of a cellwithin a tissue (e.g., the cell's position relative to neighboring cellsor the cell's position relative to the tissue microenvironment) canaffect, e.g., the cell's morphology, differentiation, fate, viability,proliferation, behavior, and signaling and cross-talk with other cellsin the tissue.

Spatial heterogeneity has been previously studied using techniques thatonly provide data for a small handful of analytes in the context of anintact tissue or a portion of a tissue, or provide a lot of analyte datafor single cells, but fail to provide information regarding the positionof the single cell in a parent biological sample (e.g., tissue sample).

Spatial gene expression technology generally allows for the capture ofgene transcripts from frozen or fixed tissues while maintaining thespatial positioning of the gene transcripts within the tissues. However,the frozen and/or fixed nature of the sample limits concurrentexperiments associated with the temporal aspect of gene expression,particularly in live cells and during conditions in which the sample ismanipulated, for example, using pharmacological compositions. Further,spatial gene expression technology workflows generally are not amenableto the use of live tissues or cells; as such, the study or tracking ofcellular activities is not available. Thus, there remains a need todevelop novel devices and methods that address a situation in whichspatial gene expression arrays can be used to detect gene expression andcellular activity concurrently in live or living tissues. Disclosedherein are systems and methods that utilize a perfusion chamber or amulti-well plate in conjunction with live tissue sections (e.g.,generated through a vibratome) or cells (e.g., cultured directly on thesubstrate) that allow for the recording of cellular activity understandard conditions or in the presence of pharmacological manipulations.

SUMMARY

The present disclosure provides methods for tracking temporalinformation, e.g., by recording cellular activity and gene expression,in combination with spatial gene expression arrays for simultaneousspatio-temporal measurements. The present disclosure also providesdevices, e.g., a perfusion chamber system or flowcell mounted to thespatial array, and a multi-well plate system, for such measurements. Insome embodiments, provided herein are drug screening methods using thespatio-temporal measurements to generate a comprehensive multiomicunderstanding of drug's impact on tissue or cell culture.

In one aspect, provided herein is a method for identifying locationand/or abundance of an analyte in a biological sample, the methodcomprising: (a) recording a cellular activity and/or an intracellulargene expression of a nucleic acid of the biological sample, and in someembodiments, the biological sample is located within a perfusion chamberin a plurality of perfusion chambers, and the perfusion chambercomprises a substrate; (b) contacting the biological sample with thesubstrate comprising a plurality of capture probes, and in someembodiments, a capture probe of the plurality of the capture probescomprises (i) a spatial barcode and (ii) a capture domain that bindsspecifically to a sequence present in the analyte; (c) extending thecapture probe using the analyte that is specifically bound to thecapture domain as a template, thereby generating an extended captureprobe; (d) amplifying the extended capture probe to produce a pluralityof extended capture probes; and (e) determining (i) all or a portion ofthe sequence of the spatial barcode, or a complement thereof, and (ii)all or a portion of the sequence of the analyte, or a complementthereof, and using the determined sequences of (i) and (ii) to identifythe location and/or abundance of the analyte in the biological sample.

In some embodiments, provided herein is the method for identifying alocation of an analyte in a biological sample, further comprising:mounting a gasket onto the substrate and mounting a cover onto thegasket to define a plurality of perfusion chambers. In some embodiments,the substrate comprises a plurality of substrate regions. In someembodiments, a substrate region of the plurality comprises the captureprobe comprising (i) the spatial barcode and (ii) the capture domainthat binds specifically to the sequence present in the analyte. In someembodiments, the gasket includes (i) a plurality of aperturescorresponding to the plurality of substrate regions, respectively, (ii)a plurality of input channels being fluidly connected to the pluralityof apertures, respectively, and (iii) a plurality of output channelsbeing fluidly connected to the plurality of apertures, respectively. Insome embodiments, the plurality of apertures of the gasket are alignedwith the plurality of substrate regions of the substrate when the gasketis mounted onto the substrate. In some embodiments, the cover includesan inlet and an outlet, the inlet being fluidly connected to theplurality of input channels when the cover is mounted onto the gasket,the outlet being fluidly connected to the plurality of output channelswhen the cover is mounted onto the gasket. In some embodiments, theplurality of perfusion chambers are defined by (i) the plurality ofsubstrate regions of the substrate, (ii) the plurality of apertures ofthe gasket that is mounted onto the substrate, and (iii) the cover thatis mounted onto the gasket.

In some embodiments, the mounting a gasket onto the substrate and themounting a cover onto the gasket to define a plurality of perfusionchambers occur prior to the recording the cellular activity or therecording the intracellular gene expression.

In some embodiments, the method further comprises perfusing a testcompound through the perfusion chamber before the recording step. Insome embodiments, the test compound is an agonist. In some embodiments,the test compound is an antagonist. In some embodiments, the testcompound activates the cellular activity. In some embodiments, the testcompound inhibits the cellular activity.

In one aspect, provided herein is a method for identifying locationand/or abundance of an analyte in a biological sample, the methodcomprising: (a) recording a cellular activity and/or an intracellulargene expression of a nucleic acid of the biological sample, and in someembodiments, the biological sample is located within a well of amulti-well plate; (b) contacting the biological sample with a substratecomprising a plurality of capture probes, and in some embodiments, acapture probe of the plurality of the capture probes comprises (i) aspatial barcode and (ii) a capture domain that binds specifically to asequence present in the analyte; (c) extending the capture probe usingthe analyte that is specifically bound to the capture domain as atemplate, thereby generating an extended capture probe; (d) amplifyingthe extended capture probe to produce a plurality of extended captureprobes; and (e) determining (i) all or a portion of the sequence of thespatial barcode, or a complement thereof, and (ii) all or a portion ofthe sequence of the analyte, or a complement thereof, and using thedetermined sequences of (i) and (ii) to identify the location and/orabundance of the analyte in the biological sample.

In some embodiments, provided herein is the method for identifying alocation of an analyte in a biological sample, further comprisingtreating the biological sample with one or more drugs.

In one aspect, provided herein is a method for determining the effect ofone or more drugs applied on a cellular activity and/or an intracellulargene expression of a nucleic acid in a biological sample, the methodcomprising: (a) culturing the biological sample on a substrate, and insome embodiments, the substrate comprises a plurality of capture probes,and

in some embodiments, a capture probe of the plurality of the captureprobes comprises (i) a spatial barcode and (ii) a capture domain that iscapable to bind specifically to a an analyte associated with thecellular activity and/or the intracellular gene expression in thebiological sample; (b) treating the biological sample with the one ormore drugs; (c) recording the cellular activity and/or the intracellulargene expression of the nucleic acid of the biological sample; (d)capturing the analyte from the biological sample, and in someembodiments, the analyte is captured by the capture domain of thecapture probe; and (e) determining the effect of the one or more drugsapplied on the cellular activity and/or the intracellular geneexpression in the biological sample, based on the level of the capturedanalyte.

In some embodiments, the multi-well plate is a 6-well plate, an 8-wellplate, a 12-well plate, a 24-well plate, a 48-well plate, or a 96-wellplate. In some embodiments, the multi-well plate is heat-resistant. Insome embodiments, the multi-well plate is capable for automaticdetecting of the cellular activity and/or the intracellular geneexpression.

In some embodiments, the plurality of capture probes are directlyattached to a surface of the well. In some embodiments, the plurality ofcapture probes are attached to the substrate. In some embodiments, thesubstrate is within the well. In some embodiments, the substrate is acoverslip. In some embodiments, the coverslip comprises plastic, metal,or glass. In some embodiments, the capture probe is attached to thesubstrate via a linkage group. In some embodiments, the linkage group isan amide group.

In some embodiments, the well or the substrate comprises a fiducialmarker.

In some embodiments, the treating step occurs prior to the recordingstep. In some embodiments, the treating step and the recording stepoccur at substantially the same time.

In some embodiments, the biological sample is treated with the one ormore drugs at substantially the same time. In some embodiments, thebiological sample is treated with the one or more drugs at differenttimes. In some embodiments, the biological sample is treated with one ormore drugs about 6 hours, 12 hours, 18 hours, 24 hours, 30 hours, 36hours, 42 hours, or 48 hours prior to fixing the biological sample.

In some embodiments, a drug of the one or more drugs is an agonist. Insome embodiments, a drug of the one or more drugs is an antagonist.

In some embodiments, the biological sample is treated with a drug, andthe drug is a small molecule.

In some embodiments, a drug of the one or more drugs activates thecellular activity and/or the intracellular gene expression. In someembodiments, a drug of the one or more drugs inhibits the cellularactivity and/or the intracellular gene expression.

In some embodiments, a drug of the one or more drugs is conjugated witha fluorophore, and/or an oligonucleotide. In some embodiments, theoligonucleotide comprises a sequence that uniquely identifies the drug.

In some embodiments, provided herein, further comprising culturing thebiological sample in the perfusion chamber or the well before therecording step.

In some embodiments, the biological sample is cultured in a culturemedium to maintain its viability. In some embodiments, the culturemedium is replaced at an appropriate interval manually or automatically.

In some embodiments, the biological sample is cultured statically.

In some embodiments, the biological sample is cultured in the perfusionchamber, and the method further comprising perfusing the culture mediumwithin the perfusion chamber.

In some embodiments, the culture medium is supplemented with oxygen.

In some embodiments, the culture medium comprises a blocking reagent. Insome embodiments, the biological sample is treated with the blockingreagent. In some embodiments, the blocking reagent is bovine serumalbumin (BSA), serum, gelatin (e.g., fish gelatin), milk (e.g., non-fatdry milk), casein, polyethylene glycol (PEG), polyvinyl alcohol (PVA),or polyvinylpyrrolidone (PVP), biotin blocking reagent, a peroxidaseblocking reagent, levamisole, Carnoy's solution, glycine, lysine, sodiumborohydride, pontamine sky blue, Sudan Black, trypan blue, FITC blockingagent, and/or acetic acid.

In some embodiments, the cellular activity comprises protein activity,phosphorylation activity, G protein-coupled receptor related activity,ion channel activity, ligand-receptor binding activity, neural activity,protein synthesis, protein expression and localization, transientoptical activity, cell-to-cell interactions, cellular morphology, orcombinations thereof.

In some embodiments, the recording comprises optical recording. In someembodiments, the optical recording comprises contacting the biologicalsample with a chemical dye. In some embodiments, the chemical dye is avoltage-sensitive dye, a pH-sensitive dye, a temperature-sensitive dye,a light-sensitive dye, an oxygen-sensitive dye, or a metal sensitivedye. In some embodiments, the chemical dye is a metal-sensitive dye(e.g., a calcium-sensitive dye).

In some embodiments, the optical recording comprises labelling thebiological sample with an indicator. In some embodiments, the indicatoris a genetically-encoded indicator. In some embodiments, thegenetically-encoded indicator is a genetically-encoded neural activityindicator, a genetically-encoded voltage indicator (GEVI) or agenetically-encoded calcium indicator (GECI, or GCaMP).

In some embodiments, the chemical dye or the indicator further comprisesa fluorophore.

In some embodiments, the optical recording is achieved by in situhybridization. In some embodiments, the optical recording is achieved byfluorescence resonance energy transfer (FRET).

In some embodiments, the optical recording comprises hybridization of aplurality of optically-labelled probes to (a) a protein, a lipid, anucleic acid or a combination thereof associated with the cellularactivity; or (b) the nucleic acid associated with the intracellular geneexpression.

In some embodiments, an optically-labelled probe of the plurality is apeptide nucleic acid (PNA) probe labelled with a fluorophore.

In some embodiments, the PNA probe is at least 10 nucleic acid, at least15 nucleic acids, at least 20 nucleic acids, at least 25 nucleic acids,at least 30 nucleic acids or more. In some embodiments, the nucleic acidhybridized to the PNA probe is DNA. In some embodiments, the nucleicacid hybridized to the PNA probe is RNA. In some embodiments, the RNA ismRNA.

In some embodiments, the optical recording is conducted usingfluorescent time-lapse microscopy.

In some embodiments, the recording step occurs prior to the contactingstep. In some embodiments, the contacting step occurs prior to therecording step. In some embodiments, the recording step and thecontacting step occur at substantially the same time.

In some embodiments, the biological sample is a tissue sample. In someembodiments, the tissue sample is a live tissue section.

In some embodiments, the tissue sample is an organoid sample or aspheroid culture sample.

In some embodiments, the tissue sample is an organoid sample. In someembodiments, the organoid sample comprises normal organoids and/orcancer organoids. In some embodiments, the organoid sample comprisescancer organoids. In some embodiments, the organoid sample comprisesintestinal organoids, liver organoids, pulmonary organoids, and/orneural organoids. In some embodiments, the organoid sample is originatedfrom disease-affected tissues (e.g., cancer tissues), normal tissue,disease-affected cells (e.g., cancer cells), normal cells,differentiated cells (e.g., somatic cells), and/or stem cells. In someembodiments, the organoid sample is originated from stem cells. In someembodiments, the stem cells are embryonic stem cells, inducedpluripotent stem cells, and/or somatic stem cells.

In some embodiments, the tissue sample is embedded in hydrogels.

In some embodiments, the biological sample is a cell culture sample. Insome embodiments, the cell sample is a primary cell culture sample. Insome embodiments, the primary cell culture sample comprises individualcells that are isolated from a fresh tissue. In some embodiments, thecell sample comprises a plurality of adherent cells. In someembodiments, the cell sample comprises a plurality of suspension cells.In some embodiments, the cell sample is transferred to the well from aseparate cell culture. In some embodiments, the cell sample comprises aplurality of disease-affected cells. In some embodiments, one or morecells of the cell sample are transfected or infected. In someembodiments, the biological sample is from a human patient or a modelanimal (e.g., a mouse).

In some embodiments, the analyte comprises a mutation. In someembodiments, the analyte comprises a single nucleotide polymorphism(SNP). In some embodiments, the analyte comprises a trinucleotiderepeat. In some embodiments, the analyte is associated with a disease orcondition.

In some embodiments, the analyte is a DNA molecule. In some embodiments,the analyte is a complementary DNA (cDNA). In some embodiments, theanalyte is an RNA molecule. In some embodiments, the RNA molecule is anmRNA molecule.

In some embodiments, the capture domain of the capture probe is blockedprior to the contacting step. In some embodiments, the capture domain isblocked by a blocking probe.

In some embodiments, the biological sample comprises a plurality of livecells, and the live cells are stained by immunofluorescence before therecording step. In some embodiments, the one or more live cells aretreated with protease K and/or trypsin.

In some embodiments, the biological sample is stained using a detectablelabel. In some embodiments, the detectable label is Can-Grunwald,Giemsa, hematoxylin and eosin (H&E), Jenner's, Leishman, Masson'strichrome, Papanicolaou, Romanowsky, silver, Sudan, Wright's, and/orPeriodic Acid Schiff (PAS). In some embodiments, the detectable label isH&E.

In some embodiments, the biological sample is imaged. In someembodiments, the biological samples is imaged using brightfield imaging.

In some embodiments, the biological sample is permeabilized after therecording step with a permeabilization agent selected from an organicsolvent, a cross-linking agent, a detergent, and an enzyme, or acombination thereof.

In some embodiments, the biological sample is fixed after contacting thebiological sample with the substrate, or culturing the biological sampleon the substrate. In some embodiments, the biological sample is fixedwith ethanol, methanol, acetone, formaldehyde (e.g., 2% formaldehyde),paraformaldehyde-Triton, glutaraldehyde, or combinations thereof.

In some embodiments, the capture probe further comprises a functionalsequence. In some embodiments, the functional sequence is a primersequence or a complement thereof. In some embodiments, the capture probefurther comprises a unique molecular sequence or a complement thereof.In some embodiments, the capture probe further comprises an additionalprimer binding sequence or a complement thereof. In some embodiments,the capture domain comprises a sequence that is substantiallycomplementary to the sequence of the analyte. In some embodiments, thecapture domain comprises a sequence that is partially complementary tothe sequence of the analyte. In some embodiments, the capture domaincomprises an oligo d(T) sequence.

In some embodiments, in the extending step, the capture probe isextended at the 3′ end. In some embodiments, the extending step utilizesa reverse transcriptase. In some embodiments, the extending steputilizes fluorescently labeled nucleotides.

In some embodiments, the biological sample is removed after theamplifying step. In some embodiments, the biological sample isenzymatically removed after the amplifying step.

In some embodiments, the amplifying step comprises amplifying (i) all orpart of sequence of the analyte bound to the capture domain, or acomplement thereof, and (ii) all or a part of the sequence of thespatial barcode, or a complement thereof.

In some embodiments, the amplifying step comprises rolling circleamplification.

In some embodiments, the amplifying step utilizes a DNA polymerase, aplurality of primers, and a plurality of nucleotides.

In some embodiments, the amplifying is not isothermal. In someembodiments, the amplifying is isothermal.

In some embodiments, the produced nucleic acid is released from theextended capture probe.

In some embodiments, the determining step comprises sequencing. In someembodiments, the determining step comprises sequencing (i) all or aportion of the sequence of the spatial barcode or the complementthereof, and (ii) all or a portion of the sequence of the analyte. Insome embodiments, the sequencing is high throughput sequencing. In someembodiments, the sequencing step comprises in situ sequencing, Sangersequencing methods, next-generation sequencing methods, and nanoporesequencing.

In some embodiments, the sequencing comprises ligating an adapter to thenucleic acid.

In one aspect, provided herein is a method for determining locationand/or abundance of an analyte in a live tissue or cell sample, themethod comprising:

-   -   (a) providing a plurality of perfusion chambers, wherein a        perfusion chamber of the plurality of perfusion chambers        comprises a substrate, a gasket mounted onto the substrate, and        a cover mounted onto the gasket, wherein the live tissue or cell        sample is located within the perfusion chamber of the plurality        of perfusion chambers, wherein        -   (1) the substrate comprises a plurality of substrate            regions, wherein a substrate region of the plurality            comprises a plurality of capture probes, wherein a capture            probe of the plurality of capture probes comprises (i) a            spatial barcode and (ii) a capture domain that binds            specifically to a sequence present in the analyte;        -   (2) the gasket comprises (i) a plurality of apertures            corresponding to the plurality of substrate regions,            respectively, (ii) a plurality of input channels being            fluidly connected to the plurality of apertures,            respectively, and (iii) a plurality of output channels being            fluidly connected to the plurality of apertures,            respectively, and wherein the plurality of apertures of the            gasket are aligned with the plurality of substrate regions            of the substrate when the gasket is mounted onto the            substrate;        -   (3) the cover comprises an inlet and an outlet, the inlet            being fluidly connected to the plurality of input channels            when the cover is mounted onto the gasket, the outlet being            fluidly connected to the plurality of output channels when            the cover is mounted onto the gasket; and        -   (4) the plurality of perfusion chambers are defined by (i)            the plurality of substrate regions of the substrate, (ii)            the plurality of apertures of the gasket that is mounted            onto the substrate, and (iii) the cover that is mounted onto            the gasket;    -   (b) perfusing one or more test compounds through the perfusion        chamber;    -   (c) recording a cellular activity and/or an intracellular gene        expression of a nucleic acid of the live tissue or cell sample,    -   (d) permeabilizing the live tissue or cell sample such that the        analyte is specifically bound to the capture domain of the        capture probe of the plurality of capture probes;    -   (e) disassembling the gasket and the cover from the substrate;    -   (f) extending the capture probe at the 3′ end using the analyte        that is specifically bound to the capture domain as a template,        thereby generating an extended capture probe;    -   (g) amplifying the extended capture probe to produce a plurality        of extended capture probes; and    -   (h) sequencing (i) all or a portion of the sequence of the        spatial barcode, or a complement thereof, and (ii) all or a        portion of the sequence of the analyte, or a complement thereof,        and using the determined sequences of (i) and (ii) to determine        the location and the location and/or abundance of the analyte in        the live tissue or cell sample.

In one aspect, provided herein is a method for identifying locationand/or abundance of an analyte in a live tissue or cell sample, themethod comprising:

-   -   (a) providing a multi-well plate comprising a substrate and a        gasket mounted onto the substrate, wherein the substrate        comprises a plurality of substrate regions, wherein a substrate        region of the plurality of substrate regions comprises capture        probes, wherein a capture probe of the plurality of capture        probes comprises (i) a spatial barcode and (ii) a capture domain        that binds specifically to a sequence present in the analyte;        wherein the gasket comprises a plurality of apertures, wherein        the gasket is configured to be mounted onto the substrate such        that the plurality of apertures are aligned with the plurality        of substrate regions, respectively; wherein a well of the        multi-well plate is defined by a substrate region of the        substrate and an aperture of the gasket; wherein the live tissue        or cell sample is located within the well of the multi-well        plate;    -   (b) treating the live tissue or cell sample with one or more        test compounds;    -   (c) recording a cellular activity and/or an intracellular gene        expression of a nucleic acid of the live tissue or cell sample;    -   (d) permeabilizing the live tissue or cell sample such that the        analyte is specifically bound to the capture domain of the        capture probe of the plurality of capture probes;    -   (e) disassembling the gasket from the substrate; extending the        capture probe at the 3′ end using the analyte that is        specifically bound to the capture domain as a template, thereby        generating an extended capture probe;    -   (g) amplifying the extended capture probe to produce a plurality        of extended capture probes; and    -   (h) sequencing (i) all or a portion of the sequence of the        spatial barcode, or a complement thereof, and (ii) all or a        portion of the sequence of the analyte, or a complement thereof,        and using the determined sequences of (i) and (ii) to identify        the location and/or abundance of the analyte in the live tissue        or cell sample.

In one aspect, provided herein is a method for identifying locationand/or abundance of an analyte in a live tissue or cell sample, themethod comprising:

-   -   (a) providing a multi-well plate, wherein a well of the        multi-well plate comprises a substrate, wherein the substrate        comprises a plurality of capture probes, wherein a capture probe        of the plurality of capture probes comprises (i) a spatial        barcode and (ii) a capture domain that binds specifically to a        sequence present in the analyte; wherein the live tissue or cell        sample is located within the well of the multi-well plate;    -   (b) treating the live tissue or cell sample with one or more        test compounds;    -   (c) recording a cellular activity and/or an intracellular gene        expression of a nucleic acid of the live tissue or cell sample;    -   (d) permeabilizing the live tissue or cell sample such that the        analyte is specifically bound to the capture domain of the        capture probe of the plurality of capture probes;    -   (e) extending the capture probe at the 3′ end using the analyte        that is specifically bound to the capture domain as a template,        thereby generating an extended capture probe; amplifying the        extended capture probe to produce a plurality of extended        capture probes; and    -   (g) sequencing (i) all or a portion of the sequence of the        spatial barcode, or a complement thereof, and (ii) all or a        portion of the sequence of the analyte, or a complement thereof,        and using the determined sequences of (i) and (ii) to identify        the location and/or abundance of the analyte in the live tissue        or cell sample.

In one aspect, provided herein is a kit comprising a) an arraycomprising a plurality of capture probes; b) a perfusion chamber definedby mounting a gasket on the array, and a cover mounted on the gasket,wherein the cover includes: (i) an inlet being fluidly connected to aplurality of input channels, and (ii) an outlet being fluidly connectedto a plurality of output channels; and c) an instruction for using thekit.

In one aspect, provided herein is a kit comprising a) a multi-well platecomprising a plurality of capture probes, wherein the plurality ofcapture probes are directly attached (e.g., printed) to a surface of awell of the multi-well plate; and b)an instruction for using the kit.

In one aspect, provided herein is a kit comprising a) a coverslipcomprising a plurality of capture probes; b) a multi-well plate, whereinthe coverslip is attached to a surface of a well of the multi-wellplate; and c) an instruction for using the kit. In some embodiments, themulti-well plate is a 6-well plate, an 8-well plate, a 12-well plate, a24-well plate, a 48-well plate, or a 96-well plate.

In one aspect, provided herein is a kit comprising a) a slide comprisinga plurality of arrays, wherein an array of the plurality of arrayscomprises capture probes; b) a gasket comprising a plurality ofapertures, wherein the gasket is configured to be mounted onto the slidesuch that the plurality of apertures are aligned with the plurality ofarrays; and c) an instruction for using the kit.

In one aspect, provided herein is an apparatus for measuring cellularactivity and/or gene expression, comprising: a gasket including aplurality of apertures, a plurality of input channels being fluidlyconnected to the plurality of apertures, respectively, and a pluralityof output channels being fluidly connected to the plurality ofapertures, respectively; and a cover configured to be mounted onto thegasket, the cover comprising: an inlet configured to be fluidlyconnected to the plurality of input channels of the gasket when thecover is mounted onto the gasket, and an outlet configured to be fluidlyconnected to the plurality of output channels of the gasket when thecover is mounted onto the gasket.

In some embodiments, the plurality of apertures includes: inlet portsthat fluidly connect to the plurality of input channels, respectively;and outlet ports that fluidly connect to the plurality of outputchannels, respectively.

In some embodiments, the apparatus described herein further comprises asubstrate having a plurality of substrate regions. In some embodiments,the gasket is configured to be mounted onto the substrate such that theplurality of apertures are aligned with the plurality of substrateregions, respectively. In some embodiments, the cover is configured tobe mounted onto the gasket opposite to the substrate. In someembodiments, a plurality of perfusion chambers are defined by (i) theplurality of substrate regions of the substrate, (ii) the plurality ofapertures of the gasket that is mounted onto the substrate, and (iii)the cover that is mounted onto the gasket

In some embodiments, the gasket is made of silicone.

In some embodiments, each of the substrate regions is configured toattach a capture probe that includes (i) a spatial barcode and (ii) acapture domain that binds to a sequence present in an analyte.

In some embodiments, the gasket has a thickness that ranges between 0.6mm and 1.0 mm.

In some embodiments, the gasket includes an upstream bore and adownstream bore. In some embodiments, the plurality of input channelsextend between the upstream bore and the inlet ports of the plurality ofapertures, respectively. In some embodiments, the plurality of outputchannel extend between the downstream bore and the outlet ports of theplurality of apertures, respectively.

In some embodiments, the plurality of input channels have differentlengths between the upstream bore and the inlet ports of the pluralityof apertures, respectively.

In some embodiments, the plurality of output channels have differentlengths between the downstream bore and the outlet ports of theplurality of apertures, respectively.

In some embodiments, the upstream bore is positioned to be opposite tothe downstream bore with respect to a center of the gasket. In someembodiments, the upstream bore is configured to be aligned with theinlet of the cover. In some embodiments, the downstream bore isconfigured to be aligned with the outlet of the cover.

In some embodiments, each of the plurality of apertures includes atleast a portion having a width that varies between the inlet port andthe outlet port.

In some embodiments, each of the plurality of apertures includes: afirst portion including the inlet port and having a first width; and asecond portion including the outlet port and having a second width.

In some embodiments, the first width of the first portion varies betweenthe inlet port and the second portion. In some embodiments, the firstwidth of the first portion gradually increases from the inlet port to aninterface between the first portion and the second portion. In someembodiments, the second width of the second portion is consistent. Insome embodiments, the first width of the first portion is identical tothe second width of the second portion at the interface between thefirst portion and the second portion.

All publications, patents, patent applications, and informationavailable on the internet and mentioned in this specification are hereinincorporated by reference to the same extent as if each individualpublication, patent, patent application, or item of information wasspecifically and individually indicated to be incorporated by reference.To the extent publications, patents, patent applications, and items ofinformation incorporated by reference contradict the disclosurecontained in the specification, the specification is intended tosupersede and/or take precedence over any such contradictory material.

Where values are described in terms of ranges, it should be understoodthat the description includes the disclosure of all possible sub-rangeswithin such ranges, as well as specific numerical values that fallwithin such ranges irrespective of whether a specific numerical value orspecific sub-range is expressly stated.

The term “each,” when used in reference to a collection of items, isintended to identify an individual item in the collection but does notnecessarily refer to every item in the collection, unless expresslystated otherwise, or unless the context of the usage clearly indicatesotherwise.

Various embodiments of the features of this disclosure are describedherein. However, it should be understood that such embodiments areprovided merely by way of example, and numerous variations, changes, andsubstitutions can occur to those skilled in the art without departingfrom the scope of this disclosure. It should also be understood thatvarious alternatives to the specific embodiments described herein arealso within the scope of this disclosure.

DESCRIPTION OF DRAWINGS

The following drawings illustrate certain embodiments of the featuresand advantages of this disclosure. These embodiments are not intended tolimit the scope of the appended claims in any manner. Like referencesymbols in the drawings indicate like elements.

FIG. 1 is a schematic diagram showing an example of a barcoded captureprobe, as described herein.

FIG. 2 is a schematic illustrating a cleavable capture probe, whereinthe cleaved capture probe can enter into a non-permeabilized cell andbind to target analytes within the sample.

FIG. 3 is a schematic diagram of an exemplary multiplexedspatially-barcoded feature.

FIG. 4 is a schematic diagram of an exemplary analyte capture agent.

FIG. 5 is a schematic diagram depicting an exemplary interaction betweena feature-immobilized capture probe 524 and an analyte capture agent526.

FIGS. 6A, 6B, and 6C are schematics illustrating how streptavidin celltags can be utilized in an array-based system to producespatially-barcoded cells or cellular contents.

FIG. 7 is a schematic illustrating a side view of a diffusion-resistantmedium.

FIGS. 8A and 8B are schematics illustrating expanded FIG. 8A and sideviews FIG. 8B of an electrophoretic transfer system configured to directtranscript analytes toward a spatially-barcoded capture probe array.

FIGS. 9A-9G show a schematic illustrating an exemplary workflow protocolutilizing an electrophoretic transfer system. NGS: next-generationsequencing.

FIG. 10A shows a schematic perspective view of an example system.

FIG. 10B shows an exploded view of an example system in FIG. 10A.

FIG. 11A shows a top view of an example gasket.

FIG. 11B shows a top view of an example substrate.

FIG. 11C shows a top view of an example gasket disposed on an examplesubstrate.

FIG. 12A shows a representative Vibratome for tissue slicing.

FIG. 12B shows preparation of live tissue sections.

FIGS. 12C and 12D show a representative perfusion chamber and assemblyof the chamber to a microscope.

FIGS. 13A-13C show a schematic illustrating mechanisms of fluorescenceresonance energy transfer (FRET). FIG. 13A shows spectral overlap duringFRET excitation. FIG. 13B demonstrates that FRET excitation occurs atdistances between the emission donor and excitation acceptor of lessthan 10 nm. FIG. 13C shows orientation of the emission donor andexcitation acceptor molecules.

FIG. 14 shows a schematic of detecting hybridization of fluorescentlylabelled oligo probes to a target mRNA sequence using FRET.

FIG. 15 shows an exemplary recording result and correspondinghybridization status for detecting gene expression of a target mRNAsequence via FRET.

FIG. 16 shows an exemplary recording result and schematic workflow fordetecting real-time response during pharmacological treatment via FRET.

FIGS. 17A-17D show exemplary gasket configurations.

FIG. 18 shows exemplary multi-well tissue culture plate configurations.

FIG. 19 shows a schematic of drug screening using patient samples. iPScells: induced pluripotent stem cells.

FIG. 20A shows a merged image of stained cells, stained cell nuclei (byDAPI), and cDNA footprint of A549 cells that were grown on top of aspatial array slide. An enlarged image of the merged image is shown onthe right.

FIG. 20B shows breakout images of individual channels in FIG. 20A.Single-channel images of stained cell nuclei by DAPI, stained cells,cDNA footprint are shown from left to right, respectively.

FIG. 20C shows a merged image of stained cells and stained cell nuclei(by DAPI) of the single-channel images shown in FIG. 20B (left); and amerged image of stained cell nuclei (by DAPI) and cDNA footprint of thesingle-channel images shown in FIG. 20B (right).

FIG. 21A shows a brightfield image of A549 cells that were grown on topof a spatial array slide. An enlarged image is shown on the left. Theround dots on the edges are fiducial markers.

FIG. 21B shows merged images of the enlarged brightfield image in FIG.21A overlaid with spots on the spatial array slide showing relativeunique molecular identifier (UMI) counts. Regions of higher cell densityare indicated by arrows.

FIG. 22A shows raw spatial UMI plots. A549 cells grown on top of thespatial arrays were untreated (left), or treated with Linsitinib for 24hours before harvesting (right). One replicate (rep1) for each culturewas obtained for detecting UMI counts. Approximate boundaries of theplots are indicated by dashed lines.

FIG. 22B shows raw spatial UMI plots. A549 cells grown on top of thespatial arrays were treated with Osimertinib for 24 hours beforeharvesting. Two replicates (rep1 and rep2) of Osimertinib-treatedcultures were obtained for detecting UMI counts. Approximate boundariesof the plots are indicated by dashed lines.

FIG. 22C shows raw spatial Gene plots. A549 cells grown on top of thespatial arrays were untreated (left), or treated with Linsitinib for 24hours before harvesting (right). One replicate (rep1) for each culturewas obtained for detecting gene counts. Approximate boundaries of theplots are indicated by dashed lines.

FIG. 22D shows raw spatial Gene plots. A549 cells grown on top of thespatial arrays were treated with Osimertinib for 24 hours beforeharvesting. Two replicates (rep1 and rep2) of Osimertinib-treatedcultures were obtained for detecting gene counts. Approximate boundariesof the plots are indicated by dashed lines.

FIGS. 23A-23C show saturation curves by drug treatment. Osimertinib-1and Osimertinib-2 are two replicates of Osimertinib-treated cells.

FIG. 23D shows complexity metrics based on the aggregated matrix by drugtreatment.

FIG. 23E shows column-wise grey UMAP (uniform manifold approximation andprojection) plot by drug treatment. Different treatment clusters areindicated by arrows.

FIG. 24A shows scatter plots of genes across drug treatment.Differentially expressed genes are indicated in the plots.

FIG. 24B shows the top differentially expressed genes between differenttreatment cultures.

FIG. 25 shows column-wise grey UMAP plots by treatment. Differenttreatment clusters are indicated by arrows.

DETAILED DESCRIPTION I. Introduction

Disclosed herein are methods and apparatus for measuring cellularactivity and/or gene expression (e.g., by optical recordings) to tracktemporal information as well as identifying a location of a targetanalyte (e.g., using capture probes attached to a surface (e.g., asubstrate) within a perfusion chamber, or a well of a multi-well plate)to track spatial information in a biological sample (e.g., a cellculture or live tissue sections). Here, the perfusion chamber and themulti-well plate are two exemplary types of culturing systems that allowlive tissue/cell samples to be recorded in situ, and culture medium canbe perfused or replaced to maintain tissue/cell viability. One directapplication of the methods described herein is to determine the effectof drugs to the cellular activity and/or gene expression, and correlatethe determined effect with the spatial information as obtained usingcapture probes, thereby providing an in-depth understanding of thedrug's effect to the biological sample.

Spatial analysis methodologies and compositions described herein canprovide a vast amount of analyte and/or expression data for a variety ofanalytes within a biological sample at high spatial resolution, whileretaining native spatial context. Spatial analysis methods andcompositions can include, e.g., the use of a capture probe including aspatial barcode (e.g., a nucleic acid sequence that provides informationas to the location or position of an analyte within a cell or a tissuesample (e.g., mammalian cell or a mammalian tissue sample) and a capturedomain that is capable of binding to an analyte (e.g., a protein and/ora nucleic acid) produced by and/or present in a cell. Spatial analysismethods and compositions can also include the use of a capture probehaving a capture domain that captures an intermediate agent for indirectdetection of an analyte. For example, the intermediate agent can includea nucleic acid sequence (e.g., a barcode) associated with theintermediate agent. Detection of the intermediate agent is thereforeindicative of the analyte in the cell or tissue sample.

Non-limiting aspects of spatial analysis methodologies and compositionsare described in U.S. Pat. Nos. 10,774,374, 10,724,078, 10,480,022,10,059,990, 10,041,949, 10,002,316, 9,879,313, 9,783,841, 9,727,810,9,593,365, 8,951,726, 8,604,182, 7,709,198, U.S. Patent ApplicationPublication Nos. 2020/239946, 2020/080136, 2020/0277663, 2020/024641,2019/330617, 2019/264268, 2020/256867, 2020/224244, 2019/194709,2019/161796, 2019/085383, 2019/055594, 2018/216161, 2018/051322,2018/0245142, 2017/241911, 2017/089811, 2017/067096, 2017/029875,2017/0016053, 2016/108458, 2015/000854, 2013/171621, WO 2018/091676, WO2020/176788, Rodrigues et al., Science 363(6434):1463-1467, 2019; Lee etal., Nat. Protoc. 10(3):442-458, 2015; Trejo et al., PLOS ONE14(2):e0212031, 2019; Chen et al., Science 348(6233):aaa6090, 2015; Gaoet al., BMC Biol. 15:50, 2017; and Gupta et al., Nature Biotechnol.36:1197-1202, 2018; the Visium Spatial Gene Expression Reagent Kits UserGuide (e.g., Rev D, dated October 2020), and/or the Visium SpatialTissue Optimization Reagent Kits User Guide (e.g., Rev D, dated October2020), both of which are available at the 10x Genomics SupportDocumentation website, and can be used herein in any combination.Further non-limiting aspects of spatial analysis methodologies andcompositions are described herein.

Some general terminologies that may be used in this disclosure can befound in Section (I)(b) of WO 2020/176788 and/or U.S. Patent ApplicationPublication No. 2020/0277663. Typically, a “barcode” is a label, oridentifier, that conveys or is capable of conveying information (e.g.,information about an analyte in a sample, a bead, and/or a captureprobe). A barcode can be part of an analyte, or independent of ananalyte. A barcode can be attached to an analyte. A particular barcodecan be unique relative to other barcodes. For the purpose of thisdisclosure, an “analyte” can include any biological substance,structure, moiety, or component to be analyzed. The term “target” cansimilarly refer to an analyte of interest.

Analytes can be broadly classified into one of two groups: nucleic acidanalytes, and non-nucleic acid analytes. Examples of non-nucleic acidanalytes include, but are not limited to, lipids, carbohydrates,peptides, proteins, glycoproteins (N-linked or O-linked), lipoproteins,phosphoproteins, specific phosphorylated or acetylated variants ofproteins, amidation variants of proteins, hydroxylation variants ofproteins, methylation variants of proteins, ubiquitylation variants ofproteins, sulfation variants of proteins, viral proteins (e.g., viralcapsid, viral envelope, viral coat, viral accessory, viralglycoproteins, viral spike, etc.), extracellular and intracellularproteins, antibodies, and antigen binding fragments. In someembodiments, the analyte(s) can be localized to subcellular location(s),including, for example, organelles, e.g., mitochondria, Golgi apparatus,endoplasmic reticulum, chloroplasts, endocytic vesicles, exocyticvesicles, vacuoles, lysosomes, etc. In some embodiments, analyte(s) canbe peptides or proteins, including without limitation antibodies andenzymes. Additional examples of analytes can be found in Section (I)(c)of WO 2020/176788 and/or U.S. Patent Application Publication No.2020/0277663. In some embodiments, an analyte can be detectedindirectly, such as through detection of an intermediate agent, forexample, a connected probe (e.g., a ligation product) or an analytecapture agent (e.g., an oligonucleotide-conjugated antibody), such asthose described herein.

A “biological sample” is typically obtained from the subject foranalysis using any of a variety of techniques including, but not limitedto, biopsy, surgery, and laser capture microscopy (LCM), and generallyincludes cells and/or other biological material from the subject. Insome embodiments, a biological sample can be a tissue section. In someembodiments, a biological sample can be a fixed and/or stainedbiological sample (e.g., a fixed and/or stained tissue section).Non-limiting examples of stains include histological stains (e.g.,hematoxylin and/or eosin) and immunological stains (e.g., fluorescentstains). In some embodiments, a biological sample (e.g., a fixed and/orstained biological sample) can be imaged. Biological samples are alsodescribed in Section (I)(d) of WO 2020/176788 and/or U.S. PatentApplication Publication No. 2020/0277663.

In some embodiments, a biological sample is permeabilized with one ormore permeabilization reagents. For example, permeabilization of abiological sample can facilitate analyte capture. Exemplarypermeabilization agents and conditions are described in Section(I)(d)(ii)(13) or the Exemplary Embodiments Section of WO 2020/176788and/or U.S. Patent Application Publication No. 2020/0277663.

Array-based spatial analysis methods involve the transfer of one or moreanalytes from a biological sample to an array of features on asubstrate, where each feature is associated with a unique spatiallocation on the array. Subsequent analysis of the transferred analytesincludes determining the identity of the analytes and the spatiallocation of the analytes within the biological sample. The spatiallocation of an analyte within the biological sample is determined basedon the feature to which the analyte is bound (e.g., directly orindirectly) on the array, and the feature's relative spatial locationwithin the array.

A “capture probe” refers to any molecule capable of capturing (directlyor indirectly) and/or labelling an analyte (e.g., an analyte ofinterest) in a biological sample. In some embodiments, the capture probeis a nucleic acid or a polypeptide. In some embodiments, the captureprobe includes a barcode (e.g., a spatial barcode and/or a uniquemolecular identifier (UMI)) and a capture domain). In some embodiments,a capture probe can include a cleavage domain and/or a functional domain(e.g., a primer-binding site, such as for next-generation sequencing(NGS)).

FIG. 1 is a schematic diagram showing an exemplary capture probe, asdescribed herein. As shown, the capture probe 102 is optionally coupledto a feature 101 by a cleavage domain 103, such as a disulfide linker.The capture probe can include a functional sequence 104 that is usefulfor subsequent processing. The functional sequence 104 can include allor a part of sequencer specific flow cell attachment sequence (e.g., aP5 or P7 sequence), all or a part of a sequencing primer sequence,(e.g., a R1 primer binding site, a R2 primer binding site), orcombinations thereof. The capture probe can also include a spatialbarcode 105. The capture probe can also include a unique molecularidentifier (UMI) sequence 106. While FIG. 1 shows the spatial barcode105 as being located upstream (5′) of UMI sequence 106, it is to beunderstood that capture probes wherein UMI sequence 106 is locatedupstream (5′) of the spatial barcode 105 is also suitable for use in anyof the methods described herein. The capture probe can also include acapture domain 107 to facilitate capture of a target analyte. Thecapture domain can have a sequence complementary to a sequence of anucleic acid analyte. The capture domain can have a sequencecomplementary to a connected probe described herein. The capture domaincan have a sequence complementary to a capture handle sequence presentin an analyte capture agent. The capture domain can have a sequencecomplementary to a splint oligonucleotide. Such splint oligonucleotide,in addition to having a sequence complementary to a capture domain of acapture probe, can have a sequence of a nucleic acid analyte, a sequencecomplementary to a portion of a connected probe described herein, and/ora capture handle sequence described herein.

The functional sequences can generally be selected for compatibilitywith any of a variety of different sequencing systems, e.g., Ion TorrentProton or PGM, Illumina sequencing instruments, PacBio, Oxford Nanopore,etc., and the requirements thereof. In some embodiments, functionalsequences can be selected for compatibility with non-commercializedsequencing systems. Examples of such sequencing systems and techniques,for which suitable functional sequences can be used, include (but arenot limited to) Ion Torrent Proton or PGM sequencing, Illuminasequencing, PacBio SMRT sequencing, and Oxford Nanopore sequencing.Further, in some embodiments, functional sequences can be selected forcompatibility with other sequencing systems, includingnon-commercialized sequencing systems.

In some embodiments, the spatial barcode 105 and functional sequences104 are common to all of the probes attached to a given feature. In someembodiments, the UMI sequence 106 of a capture probe attached to a givenfeature is different from the UMI sequence of a different capture probeattached to the given feature.

FIG. 2 is a schematic illustrating a cleavable capture probe, whereinthe cleaved capture probe can enter into a non-permeabilized cell andbind to analytes within the sample. The capture probe 201 contains acleavage domain 202, a cell penetrating peptide 203, a reporter molecule204, and a disulfide bond (—S—S—). 205 represents all other parts of acapture probe, for example a spatial barcode and a capture domain.

FIG. 3 is a schematic diagram of an exemplary multiplexedspatially-barcoded feature. In FIG. 3, the feature 301 can be coupled tospatially-barcoded capture probes, wherein the spatially-barcoded probesof a particular feature can possess the same spatial barcode, but havedifferent capture domains designed to associate the spatial barcode ofthe feature with more than one target analyte. For example, a featuremay be coupled to four different types of spatially-barcoded captureprobes, each type of spatially-barcoded capture probe possessing thespatial barcode 302. One type of capture probe associated with thefeature includes the spatial barcode 302 in combination with a poly(T)capture domain 303, designed to capture mRNA target analytes. A secondtype of capture probe associated with the feature includes the spatialbarcode 302 in combination with a random N-mer capture domain 304 forgDNA analysis. A third type of capture probe associated with the featureincludes the spatial barcode 302 in combination with a capture domaincomplementary to a capture handle sequence of an analyte capture agentof interest 305. A fourth type of capture probe associated with thefeature includes the spatial barcode 302 in combination with a capturedomain that can specifically bind a nucleic acid molecule 306 that canfunction in a CRISPR assay (e.g., CRISPR/Cas9). While only fourdifferent capture probe-barcoded constructs are shown in FIG. 3,capture-probe barcoded constructs can be tailored for analyses of anygiven analyte associated with a nucleic acid and capable of binding withsuch a construct. For example, the schemes shown in FIG. 3 can also beused for concurrent analysis of other analytes disclosed herein,including, but not limited to: (a) mRNA, a lineage tracing construct,cell surface or intracellular proteins and metabolites, and gDNA; (b)mRNA, accessible chromatin (e.g., ATAC-seq, DNase-seq, and/or MNase-seq)cell surface or intracellular proteins and metabolites, and aperturbation agent (e.g., a CRISPR crRNA/sgRNA, TALEN, zinc fingernuclease, and/or antisense oligonucleotide as described herein); (c)mRNA, cell surface or intracellular proteins and/or metabolites, abarcoded labelling agent (e.g., the MHC multimers described herein), anda V(D)J sequence of an immune cell receptor (e.g., T-cell receptor). Insome embodiments, a perturbation agent can be a small molecule, anantibody, a drug, an aptamer, a miRNA, a physical environmental (e.g.,temperature change), or any other known perturbation agents. See, e.g.,Section (II)(b) (e.g., subsections (i)-(vi)) of WO 2020/176788 and/orU.S. Patent Application Publication No. 2020/0277663. Generation ofcapture probes can be achieved by any appropriate method, includingthose described in Section (II)(d)(ii) of WO 2020/176788 and/or U.S.Patent Application Publication No. 2020/0277663.

In some embodiments, more than one analyte type (e.g., nucleic acids andproteins) from a biological sample can be detected (e.g., simultaneouslyor sequentially) using any appropriate multiplexing technique, such asthose described in Section (IV) of WO 2020/176788 and/or U.S. PatentApplication Publication No. 2020/0277663.

In some embodiments, detection of one or more analytes (e.g., proteinanalytes) can be performed using one or more analyte capture agents. Asused herein, an “analyte capture agent” refers to an agent thatinteracts with an analyte (e.g., an analyte in a biological sample) andwith a capture probe (e.g., a capture probe attached to a substrate or afeature) to identify the analyte. In some embodiments, the analytecapture agent includes: (i) an analyte binding moiety (e.g., that bindsto an analyte), for example, an antibody or antigen-binding fragmentthereof; (ii) analyte binding moiety barcode; and (iii) a capture handlesequence. As used herein, the term “analyte binding moiety barcode”refers to a barcode that is associated with or otherwise identifies theanalyte binding moiety. As used herein, the term “analyte capturesequence” or “capture handle sequence” refers to a region or moietyconfigured to hybridize to, bind to, couple to, or otherwise interactwith a capture domain of a capture probe. In some embodiments, a capturehandle sequence is complementary to a capture domain of a capture probe.In some cases, an analyte binding moiety barcode (or portion thereof)may be able to be removed (e.g., cleaved) from the analyte captureagent.

FIG. 4 is a schematic diagram of an exemplary analyte capture agent 402comprised of an analyte-binding moiety 404 and an analyte-binding moietybarcode domain 408. The exemplary analyte -binding moiety 404 is amolecule capable of binding to an analyte 406 and the analyte captureagent is capable of interacting with a spatially-barcoded capture probe.The analyte -binding moiety can bind to the analyte 406 with highaffinity and/or with high specificity. The analyte capture agent caninclude an analyte -binding moiety barcode domain 408, a nucleotidesequence (e.g., an oligonucleotide), which can hybridize to at least aportion or an entirety of a capture domain of a capture probe. Theanalyte-binding moiety barcode domain 408 can comprise an analytebinding moiety barcode and a capture handle sequence described herein.The analyte -binding moiety 404 can include a polypeptide and/or anaptamer. The analyte -binding moiety 404 can include an antibody orantibody fragment (e.g., an antigen-binding fragment).

FIG. 5 is a schematic diagram depicting an exemplary interaction betweena feature-immobilized capture probe 524 and an analyte capture agent526. The feature-immobilized capture probe 524 can include a spatialbarcode 508 as well as functional sequences 506 and UMI 510, asdescribed elsewhere herein. The capture probe can also include a capturedomain 512 that is capable of binding to an analyte capture agent 526.The analyte capture agent 526 can include a functional sequence 518,analyte binding moiety barcode 516, and a capture handle sequence 514that is capable of binding to the capture domain 512 of the captureprobe 524. The analyte capture agent can also include a linker 520 thatallows the capture agent barcode domain 516 to couple to the analytebinding moiety 522.

FIGS. 6A, 6B, and 6C are schematics illustrating how streptavidin celltags can be utilized in an array-based system to produce aspatially-barcoded cell or cellular contents. For example, as shown inFIG. 6A, peptide-bound major histocompatibility complex (MHC) can beindividually associated with biotin (β2m) and bound to a streptavidinmoiety such that the streptavidin moiety comprises multiple pMHCmoieties. Each of these moieties can bind to a TCR such that thestreptavidin binds to a target T-cell via multiple MHC/TCR bindinginteractions. Multiple interactions synergize and can substantiallyimprove binding affinity. Such improved affinity can improve labellingof T-cells and also reduce the likelihood that labels will dissociatefrom T-cell surfaces. As shown in FIG. 6B, a capture agent barcodedomain 601 can be modified with streptavidin 602 and contacted withmultiple molecules of biotinylated MHC 603 such that the biotinylatedMHC 603 molecules are coupled with the streptavidin conjugated captureagent barcode domain 601. The result is a barcoded MHC multimer complex605. As shown in FIG. 6B, the capture agent barcode domain sequence 601can identify the MHC as its associated label and also includes optionalfunctional sequences such as sequences for hybridization with otheroligonucleotides. As shown in FIG. 6C, one example oligonucleotide iscapture probe 606 that comprises a complementary sequence (e.g., rGrGrGcorresponding to C C C), a barcode sequence and other functionalsequences, such as, for example, a UMI, an adapter sequence (e.g.,comprising a sequencing primer sequence (e.g., R1 or a partial R1(“pR1”), R2), a flow cell attachment sequence (e.g., P5 or P7 or partialsequences thereof)), etc. In some cases, capture probe 606 may at firstbe associated with a feature (e.g., a gel bead) and released from thefeature. In other embodiments, capture probe 606 can hybridize with acapture agent barcode domain 601 of the MHC-oligonucleotide complex 605.The hybridized oligonucleotides (Spacer C C C and Spacer rGrGrG) canthen be extended in primer extension reactions such that constructscomprising sequences that correspond to each of the two spatial barcodesequences (the spatial barcode associated with the capture probe, andthe barcode associated with the MHC-oligonucleotide complex) aregenerated. In some cases, one or both of the corresponding sequences maybe a complement of the original sequence in capture probe 606 or captureagent barcode domain 601. In other embodiments, the capture probe andthe capture agent barcode domain are ligated together. The resultingconstructs can be optionally further processed (e.g., to add anyadditional sequences and/or for clean-up) and subjected to sequencing.As described elsewhere herein, a sequence derived from the capture probe606 spatial barcode sequence may be used to identify a feature and thesequence derived from spatial barcode sequence on the capture agentbarcode domain 601 may be used to identify the particular peptide MHCcomplex 604 bound on the surface of the cell (e.g., when usingMHC-peptide libraries for screening immune cells or immune cellpopulations).

Additional description of analyte capture agents can be found in Section(II)(b)(ix) of WO 2020/176788 and/or Section (II)(b)(viii) U.S. PatentApplication Publication No. 2020/0277663.

There are at least two methods to associate a spatial barcode with oneor more neighboring cells, such that the spatial barcode identifies theone or more cells, and/or contents of the one or more cells, asassociated with a particular spatial location. One method is to promoteanalytes or analyte proxies (e.g., intermediate agents) out of a celland towards a spatially-barcoded array (e.g., includingspatially-barcoded capture probes). Another method is to cleavespatially-barcoded capture probes from an array and promote thespatially-barcoded capture probes towards and/or into or onto thebiological sample.

In some cases, capture probes may be configured to prime, replicate, andconsequently yield optionally barcoded extension products from atemplate (e.g., a DNA or RNA template, such as an analyte or anintermediate agent (e.g., a connected probe (e.g., a ligation product)or an analyte capture agent), or a portion thereof), or derivativesthereof (see, e.g., Section (II)(b)(vii) of WO 2020/176788 and/or U.S.Patent Application Publication No. 2020/0277663 regarding extendedcapture probes). In some cases, capture probes may be configured to forma connected probe (e.g., a ligation product) with a template (e.g., aDNA or RNA template, such as an analyte or an intermediate agent, orportion thereof), thereby creating ligations products that serve asproxies for a template.

As used herein, an “extended capture probe” refers to a capture probehaving additional nucleotides added to the terminus (e.g., 3′ or 5′ end)of the capture probe thereby extending the overall length of the captureprobe. For example, an “extended 3′ end” indicates additionalnucleotides were added to the most 3′ nucleotide of the capture probe toextend the length of the capture probe, for example, by polymerizationreactions used to extend nucleic acid molecules including templatedpolymerization catalyzed by a polymerase (e.g., a DNA polymerase or areverse transcriptase). In some embodiments, extending the capture probeincludes adding to a 3′ end of a capture probe a nucleic acid sequencethat is complementary to a nucleic acid sequence of an analyte orintermediate agent specifically bound to the capture domain of thecapture probe. In some embodiments, the capture probe is extended usingreverse transcription. In some embodiments, the capture probe isextended using one or more DNA polymerases. The extended capture probesinclude the sequence of the capture probe and the sequence of thespatial barcode of the capture probe. In some embodiments, extendedcapture probes are amplified (e.g., in bulk solution or on the array) toyield quantities that are sufficient for downstream analysis, e.g., viaDNA sequencing. In some embodiments, extended capture probes (e.g., DNAmolecules) act as templates for an amplification reaction (e.g., apolymerase chain reaction). Additional variants of spatial analysismethods, including in some embodiments, an imaging step, are describedin Section (II)(a) of WO 2020/176788 and/or U.S. Patent ApplicationPublication No. 2020/0277663. Analysis of captured analytes (and/orintermediate agents or portions thereof), for example, including sampleremoval, extension of capture probes, sequencing (e.g., of a cleavedextended capture probe and/or a cDNA molecule complementary to anextended capture probe), sequencing on the array (e.g., using, forexample, in situ hybridization or in situ ligation approaches), temporalanalysis, and/or proximity capture, is described in Section (II)(g) ofWO 2020/176788 and/or U.S. Patent Application Publication No.2020/0277663. Some quality control measures are described in Section(II)(h) of WO 2020/176788 and/or U.S. Patent Application Publication No.2020/0277663.

Spatial information can provide information of biological and/or medicalimportance. For example, the methods and compositions described hereincan allow for: identification of one or more biomarkers (e.g.,diagnostic, prognostic, and/or for determination of efficacy of atreatment) of a disease or disorder; identification of a candidate drugtarget for treatment of a disease or disorder; identification (e.g.,diagnosis) of a subject as having a disease or disorder; identificationof stage and/or prognosis of a disease or disorder in a subject;identification of a subject as having an increased likelihood ofdeveloping a disease or disorder; monitoring of progression of a diseaseor disorder in a subject; determination of efficacy of a treatment of adisease or disorder in a subject; identification of a patientsubpopulation for which a treatment is effective for a disease ordisorder; modification of a treatment of a subject with a disease ordisorder; selection of a subject for participation in a clinical trial;and/or selection of a treatment for a subject with a disease ordisorder.

Spatial information can provide information of biological importance.For example, the methods and compositions described herein can allowfor: identification of transcriptome and/or proteome expression profiles(e.g., in healthy and/or diseased tissue); identification of multipleanalyte types in close proximity (e.g., nearest neighbor analysis);determination of up- and/or down-regulated genes and/or proteins indiseased tissue; characterization of tumor microenvironments;characterization of tumor immune responses; characterization of cellstypes and their co-localization in tissue; and identification of geneticvariants within tissues (e.g., based on gene and/or protein expressionprofiles associated with specific disease or disorder biomarkers).

Typically, for spatial array-based methods, a substrate functions as asupport for direct or indirect attachment of capture probes to featuresof the array. A “feature” is an entity that acts as a support orrepository for various molecular entities used in spatial analysis. Insome embodiments, some or all of the features in an array arefunctionalized for analyte capture. Exemplary substrates are describedin Section (II)(c) of WO 2020/176788 and/or U.S. Patent ApplicationPublication No. 2020/0277663. Exemplary features and geometricattributes of an array can be found in Sections (II)(d)(i),(II)(d)(iii), and (II)(d)(iv) of WO 2020/176788 and/or U.S. PatentApplication Publication No. 2020/0277663.

Generally, analytes and/or intermediate agents (or portions thereof) canbe captured when contacting a biological sample with a substrateincluding capture probes (e.g., a substrate with capture probesembedded, spotted, printed, fabricated on the substrate, or a substratewith features (e.g., beads, wells) comprising capture probes). As usedherein, “contact,” “contacted,” and/or “contacting,” a biological samplewith a substrate refers to any contact (e.g., direct or indirect) suchthat capture probes can interact (e.g., bind covalently ornon-covalently (e.g., hybridize)) with analytes from the biologicalsample. Capture can be achieved actively (e.g., using electrophoresis)or passively (e.g., using diffusion). Analyte capture is furtherdescribed in Section (II)(e) of WO 2020/176788 and/or U.S. PatentApplication Publication No. 2020/0277663.

In some cases, spatial analysis can be performed by attaching and/orintroducing a molecule (e.g., a peptide, a lipid, or a nucleic acidmolecule) having a barcode (e.g., a spatial barcode) to a biologicalsample (e.g., to a cell in a biological sample). In some embodiments, aplurality of molecules (e.g., a plurality of nucleic acid molecules)having a plurality of barcodes (e.g., a plurality of spatial barcodes)are introduced to a biological sample (e.g., to a plurality of cells ina biological sample) for use in spatial analysis. In some embodiments,after attaching and/or introducing a molecule having a barcode to abiological sample, the biological sample can be physically separated(e.g., dissociated) into single cells or cell groups for analysis. Somesuch methods of spatial analysis are described in Section (III) of WO2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.

In some cases, spatial analysis can be performed by detecting multipleoligonucleotides that hybridize to an analyte. In some instances, forexample, spatial analysis can be performed using RNA-templated ligation(RTL). Methods of RTL have been described previously. See, e.g., Credleet al., Nucleic Acids Res. 2017 Aug. 21;45(14):e128. Typically, RTLincludes hybridization of two oligonucleotides to adjacent sequences onan analyte (e.g., an RNA molecule, such as an mRNA molecule). In someinstances, the oligonucleotides are DNA molecules. In some instances,one of the oligonucleotides includes at least two ribonucleic acid basesat the 3′ end and/or the other oligonucleotide includes a phosphorylatednucleotide at the 5′ end. In some instances, one of the twooligonucleotides includes a capture domain (e.g., a poly(A) sequence, anon-homopolymeric sequence). After hybridization to the analyte, aligase (e.g., SplintR ligase) ligates the two oligonucleotides together,creating a connected probe (e.g., a ligation product). In someinstances, the two oligonucleotides hybridize to sequences that are notadjacent to one another. For example, hybridization of the twooligonucleotides creates a gap between the hybridized oligonucleotides.In some instances, a polymerase (e.g., a DNA polymerase) can extend oneof the oligonucleotides prior to ligation. After ligation, the connectedprobe (e.g., a ligation product) is released from the analyte. In someinstances, the connected probe (e.g., a ligation product) is releasedusing an endonuclease (e.g., RNAse H). The released connected probe(e.g., a ligation product) can then be captured by capture probes (e.g.,instead of direct capture of an analyte) on an array, optionallyamplified, and sequenced, thus determining the location and optionallythe abundance of the analyte in the biological sample.

During analysis of spatial information, sequence information for aspatial barcode associated with an analyte is obtained, and the sequenceinformation can be used to provide information about the spatialdistribution of the analyte in the biological sample. Various methodscan be used to obtain the spatial information. In some embodiments,specific capture probes and the analytes they capture are associatedwith specific locations in an array of features on a substrate. Forexample, specific spatial barcodes can be associated with specific arraylocations prior to array fabrication, and the sequences of the spatialbarcodes can be stored (e.g., in a database) along with specific arraylocation information, so that each spatial barcode uniquely maps to aparticular array location.

Alternatively, specific spatial barcodes can be deposited atpredetermined locations in an array of features during fabrication suchthat at each location, only one type of spatial barcode is present sothat spatial barcodes are uniquely associated with a single feature ofthe array. Where necessary, the arrays can be decoded using any of themethods described herein so that spatial barcodes are uniquelyassociated with array feature locations, and this mapping can be storedas described above.

When sequence information is obtained for capture probes and/or analytesduring analysis of spatial information, the locations of the captureprobes and/or analytes can be determined by referring to the storedinformation that uniquely associates each spatial barcode with an arrayfeature location. In this manner, specific capture probes and capturedanalytes are associated with specific locations in the array offeatures. Each array feature location represents a position relative toa coordinate reference point (e.g., an array location, a fiducialmarker) for the array. Accordingly, each feature location has an“address” or location in the coordinate space of the array.

Some exemplary spatial analysis workflows are described in the ExemplaryEmbodiments section of WO 2020/176788 and/or U.S. Patent ApplicationPublication No. 2020/0277663. See, for example, the Exemplary embodimentstarting with “In some non-limiting examples of the workflows describedherein, the sample can be immersed . . . ” of WO 2020/176788 and/or U.S.Patent Application Publication No. 2020/0277663. See also, e.g., theVisium Spatial Gene Expression Reagent Kits User Guide (e.g., Rev D,dated October 2020), and/or the Visium Spatial Tissue OptimizationReagent Kits User Guide (e.g., Rev D, dated October 2020). In someembodiments, spatial analysis can be performed using dedicated hardwareand/or software, such as any of the systems described in Sections(II)(e)(ii) and/or (V) of WO 2020/176788 and/or U.S. Patent ApplicationPublication No. 2020/0277663, or any of one or more of the devices ormethods described in Sections Control Slide for Imaging, Methods ofUsing Control Slides and Substrates for, Systems of Using Control Slidesand Substrates for Imaging, and/or Sample and Array Alignment Devicesand Methods, Informational labels of WO 2020/123320.

Suitable systems for performing spatial analysis can include componentssuch as a chamber (e.g., a flow cell or sealable, fluid-tight chamber)for containing a biological sample. The biological sample can be mountedfor example, in a biological sample holder. One or more fluid chamberscan be connected to the chamber and/or the sample holder via fluidconduits, and fluids can be delivered into the chamber and/or sampleholder via fluidic pumps, vacuum sources, or other devices coupled tothe fluid conduits that create a pressure gradient to drive fluid flow.One or more valves can also be connected to fluid conduits to regulatethe flow of reagents from reservoirs to the chamber and/or sampleholder.

The systems can optionally include a control unit that includes one ormore electronic processors, an input interface, an output interface(such as a display), and a storage unit (e.g., a solid state storagemedium such as, but not limited to, a magnetic, optical, or other solidstate, persistent, writeable and/or re-writeable storage medium). Thecontrol unit can optionally be connected to one or more remote devicesvia a network. The control unit (and components thereof) can generallyperform any of the steps and functions described herein. Where thesystem is connected to a remote device, the remote device (or devices)can perform any of the steps or features described herein. The systemscan optionally include one or more detectors (e.g., CCD, CMOS) used tocapture images. The systems can also optionally include one or morelight sources (e.g., LED-based, diode-based, lasers) for illuminating asample, a substrate with features, analytes from a biological samplecaptured on a substrate, and various control and calibration media.

The systems can optionally include software instructions encoded and/orimplemented in one or more of tangible storage media and hardwarecomponents such as application specific integrated circuits. Thesoftware instructions, when executed by a control unit (and inparticular, an electronic processor) or an integrated circuit, can causethe control unit, integrated circuit, or other component executing thesoftware instructions to perform any of the method steps or functionsdescribed herein.

In some cases, the systems described herein can detect (e.g., registeran image) the biological sample on the array. Exemplary methods todetect the biological sample on an array are described in PCTApplication No. 2020/061064 and/or U.S. patent application Ser. No.16/951,854.

Prior to transferring analytes from the biological sample to the arrayof features on the substrate, the biological sample can be aligned withthe array. Alignment of a biological sample and an array of featuresincluding capture probes can facilitate spatial analysis, which can beused to detect differences in analyte presence and/or level withindifferent positions in the biological sample, for example, to generate athree-dimensional map of the analyte presence and/or level. Exemplarymethods to generate a two- and/or three-dimensional map of the analytepresence and/or level are described in PCT Application No. 2020/053655and spatial analysis methods are generally described in WO 2020/061108and/or U.S. patent application Ser. No. 16/951,864.

In some cases, a map of analyte presence and/or level can be aligned toan image of a biological sample using one or more fiducial markers,e.g., objects placed in the field of view of an imaging system whichappear in the image produced, as described in the Substrate AttributesSection, Control Slide for Imaging Section of WO 2020/123320, PCTApplication No. 2020/061066, and/or U.S. patent application Ser. No.16/951,843. Fiducial markers can be used as a point of reference ormeasurement scale for alignment (e.g., to align a sample and an array,to align two substrates, to determine a location of a sample or array ona substrate relative to a fiducial marker) and/or for quantitativemeasurements of sizes and/or distances.

II. Simultaneous Spatio-Temporal Measurement of Gene Expression andCellular Activity

Spatial transcriptomics is performed on biological samples, for exampletissue sections that are in some manner processed prior to assaying.Spatial workflows allow for the detection of, for example, geneexpression from frozen or fixed tissues while maintaining the spatialposition of the gene expression within the tissue. The disclosed methodsand systems allow for the utilization of a spatial assay platform inconjunction with live tissue sections or cells for the study of, forexample, pharmacological drug discovery, protein interactions, or othercellular activities that are best studied using live tissues or cells asa starting material.

(a) Biological sample

In some embodiments, disclosed herein are methods of detecting cellularactivity and/or gene expression in a biological sample. In someinstances, the biological sample is a tissue sample. In someembodiments, the tissue sample is a live tissue section. In someembodiments, the live tissue sample is sectioned (e.g., using avibratome or any slicing instruments known in the art) from a freshtissue. In some embodiments, the live tissue section can be treated(e.g., an enzymatic dissociation) to release individual cells, such thatthe isolated individual cells can be analyzed using the methodsdescribed herein. In some embodiments, the tissue sample is an intacttissue. In some embodiments, the tissue sample is a semi-intact tissue.

In some embodiments, the live tissue sample is cultured (e.g., in atissue culture medium) in the perfusion chamber or the multi-well platedescribed herein before a recording step. Recording as used hereinincludes but is not limited to determining or measuring the abundance ofan analyte or biological activity in a sample. In some instances,recording includes imaging the sample using any of the method stepsdisclosed herein. In some instances, the recording includes determiningthe abundance of an analyte (e.g., protein, RNA, DNA) or biologicalactivity in a sample. In some instances, recording (e.g., determining)is performed using qualitative techniques. In some instances, recording(e.g., determining) is performed using quantitative techniques. In someinstances, recording includes detecting the presence of and/or abundanceof a reporter or detectable marker (e.g., fluorescent proteindetection). Recording a cellular or biological activity includesmeasuring the presence or abundance of an activity in a cell. Activitiesinclude but are not limited to protein activity (e.g., kinase activity),phosphorylation activity, G protein-coupled receptor related activity,ion channel activity (e.g., switch between open and closedconformation), ligand-receptor binding activity, neural activity (e.g.,neuronal action potentials), protein synthesis (e.g., transcription ortranslation) activity, protein expression and localization (e.g.,sub-cellular organelle protein expression and trafficking), transientoptical activity (e.g., optical reporter gene expression), cell-to-cellinteraction, cellular morphology, vesicular trafficking (e.g.,exocytosis or endocytosis), protein translocation and/or proteinpost-translational modifications (e.g., ubiquitination orglycosylation). In some embodiments, the cellular activity includesprocesses in cell signaling pathways or cascades. In some embodiments,the cellular activity includes conformational changes of biomolecules(e.g., proteins or nucleic acids).

In some embodiments, the live tissue sample is cultured in a separatetissue culture or a substrate (e.g., a coverslip, sponge gels, etc.),then transferred to the perfusion chamber or the multi-well platedescribed herein. In some embodiments, additional compounds (e.g.,artificial cerebrospinal fluid) are supplemented to the tissue culturemedium to maintain cell viability of the live tissue sample (e.g., aneuronal tissue). In some embodiments, the live tissue sample isdirectly placed in the perfusion chamber or the multi-well plate,without culturing before the recording step. For example, the livetissue sample can be sectioned from a fresh tissue and directly placedin the perfusion chamber or the multi-well plate before the recordingstep. In some embodiments, the sectioned live tissue sample is placed ina suspension oxygenated medium to maintain tissue viability.

In some embodiments, the tissue sample is an organoid sample. Anorganoid is a miniaturized and simplified version of an organ producedin vitro in three dimensions that shows realistic micro-anatomy. Forexample, some organoids are derived from one or a few cells from atissue, embryonic stem cells or induced pluripotent stem cells, whichcan self-organize in three-dimensional culture owing to theirself-renewal and differentiation capacities. In some embodiments, theorganoid sample is a cerebral organoid, gut organoid, intestinalorganoid (e.g., small intestinal organoid), stomach (or gastric)organoid, lingual organoid, thyroid organoid, thymic organoid,testicular organoid, hepatic organoid, pancreatic organoid, epithelialorganoid, liver organoid, pulmonary organoid, neural organoid, brainorganoid, lung organoid, kidney organoid, embryonic organoid,blastocyst-like organoid, cardiac organoid, retinal organoid, or anycombinations thereof. In some embodiments, the organoid sample isoriginated from disease-affected tissues (e.g., cancer tissues) ornormal tissues. In some embodiments, the organoid sample is originatedfrom disease-affected cells (e.g., cancer cells) or normal cells. Insome embodiments, the organoid is originated from stem cells (e.g.,embryonic stem cells, induced pluripotent stem cells, and/or somaticstem cells), or differentiated cells (e.g., somatic cells). Details canbe found, e.g., in Xu, et al., Journal of Hematology & Oncology 11.1(2018): 116; and Clevers, Hans, Cell 165.7 (2016): 1586-1597; each ofwhich is incorporated herein by reference by its entirety.

In some embodiments, overall tissue viability of cells in the tissuesample is at least or about 60%, at least or about 65%, at least orabout 70%, at least or about 75%, at least or about 80%, at least orabout 85%, at least or about 90%, at least or about 95%, at least orabout 96%, at least or about 97%, at least or about 98%, at least orabout 99%, or 100%.

In some embodiments, the biological sample is a cell sample (e.g., cellspresent in a cell culture). In some embodiments, the cell sample iscultured in the perfusion chamber or the multi-well plate before therecording step, e.g., for at least 1 hour, at least 2 hours, at least 3hours, at least 4 hours, at least 6 hours, at least 12 hours, at least 1day, at least 2 days, at least 3 days, at least 4 days, at least 5 days,at least a week, at least 2 weeks, at least 3 weeks, or longer. In someembodiments, the cells of the cell sample are directly cultured in theperfusion chamber or the multi-well plate, e.g., by seeding the cells atan appropriate density known in the art. The perfusion chamber or themulti-well plate can serve as a cell culture container and a culturemedium can be perfused (or added) within the perfusion chamber or themulti-well plate to maintain viability of the cells. In someembodiments, the cell sample is transferred to the perfusion chamber orthe multi-well plate from a separate cell culture. In some embodiments,the cell sample is a cell line.

In some embodiments, at least one cell in the cell sample is transfectedor infected by methods known in the art. In some embodiments, the cellsample is infected by a viral vector, e.g., a virus that includes anucleic acid that encodes at least one protein of interest. Exemplaryviral vectors include adenoviruses (reviewed in Altaras et al., 2005,Adv. Biochem. Eng. Biotechnol., 99:193-260), adeno-associated viruses(reviewed in Park et al., 2008, Front. Biosci., 13:2653-59; see alsoWilliams, 2007, Mol. Ther., 15:2053-54), parvoviruses, lentiviruses,retroviruses (reviewed in Tai et al., 2008, Front. Biosci., 13:3083-95),and the herpes simplex virus. Methods of delivery of nucleic acids arereviewed in Patil et al., 2005, AAPS J., 9 7:E61-77, which isincorporated herein by reference in its entirety.

In some embodiments, the cell sample is a primary cell culture sample.The primary cell culture sample comprises cells dissociated from freshtissue samples. Additional nutrients may be supplemented to the culturemedium according to specific cell types (e.g., neuron, epithelial cells,or endothelial cells) to maintain cell viability. In some embodiments,the cell sample is an immortalized cell line (e.g., a human cell line)sample. In some embodiments, the cell sample comprises adherent cellsand/or suspension cells.

In some embodiments, overall viability of cells in the cell sample is atleast or about 60%, at least or about 65%, at least or about 70%, atleast or about 75%, at least or about 80%, at least or about 85%, atleast or about 90%, at least or about 95%, at least or about 96%, atleast or about 97%, at least or about 98%, at least or about 99%, or100%.

In some embodiments, the biological sample is a three dimensional (3D)culture sample. In some embodiments, the 3D culture sample is anorganoid sample (e.g., comprising one or more types of organoids). Insome embodiments, the 3D culture sample is a spheroid sample (e.g.,comprising one or more types of spheroids). In some embodiments, thebiological sample is embedded in hydrogels.

In some embodiments, the biological sample is from a human (e.g., humanpatients). In some embodiments, the biological sample is from an animalmodel (e.g., mice).

The analyte can be any analyte disclosed herein, or multiples thereof.In some instances, the analyte is a nucleic acid. In some instances, theanalyte is a protein. In some instances, both a nucleic acid analyte anda protein analyte are measured from the same sample. In some instances,the methods disclosed herein include measuring and/or determining therelative abundance of an analyte compared to a reference sample. In someinstances, the methods disclosed herein include determining the tertiaryor quaternary structure of the analyte. In some instances, the methodsdisclosed herein identify one or more post-translational modificationson an analyte. This includes, without limitation, the presence andabundance of one or more post-translational modifications. In someinstances, the methods disclosed herein determine the enzymatic activityof an analyte.

In some instances, the methods disclosed herein determine the locationof an analyte. In some instances, the location of the analyte is fluidover time. That is, the location of an analyte can vary depending on itsfunction. For example, in some instances, the methods disclosed hereinallow a user to determine analyte translocation or trafficking acrossany organelle in the cell (e.g., as described herein). In someinstances, translocation or trafficking occurs in or around anendoplasmic reticulum (ER) in a cell. In some instances, translocationor trafficking occurs in or around a Golgi apparatus in a cell. In someinstances, an analyte can be detected as associating with a cell ornuclear membrane surface.

In some embodiments, the biological sample is treated with a blockingreagent described herein. In some instances, the blocking reagent canprevent molecular (e.g., test compounds or drugs described herein) orcellular (e.g., live cells) adhesion to a capture probe.

(b) Perfusion Chamber

Referring to FIGS. 10A-10B and 11A-11C, an example system 3000 isdescribed which can be used for capturing temporal aspects of geneexpression in a biological sample. FIG. 10A is a schematic perspectiveview of the system 3000, and FIG. 10B is an exploded view of the system3000 of FIG. 10A. As described herein, the system 3000 is configured todefine one or more chambers that can be used for measuring cellularactivity or gene expression in a biological sample. In some embodiments,a chamber is an array area of a spatial transcriptomics slide, forexample an array area of a Visium gene expression slide wherein thearray area comprises a plurality of capture probes as described herein.

The system 3000 can include a gasket 3002 and a cover 3004. The system3000 may further include a substrate 3006. In general, as illustrated inFIG. 10A, the gasket 3002 and the cover 3004 are configured to bereversibly mounted onto the substrate 3006 to define chambers thatcontain biological samples placed on the substrate 3006. Such chamberscan be used as perfusion chambers into which fluids are introduced forvarious analyses, such as measuring cellular activities or geneexpression. As described herein, the system 3000 is configured to beable to achieve laminar flow so that multiple samples (e.g., cells,tissues, etc.) can be contacted with fluid at the same time.

As shown in FIGS. 10B and 11B, the substrate 3006 includes one or moresubstrate regions 3008, each of which is configured to receive abiological sample. In some implementations, the substrate 3006 includesa plurality of substrate regions 3008 for placing a plurality ofsamples. The substrate regions 3008 can comprise a plurality of captureprobes, as described herein. The capture probes can include a spatialbarcode and a capture domain that binds to a sequence present in ananalyte. The substrate regions 3008 can be arranged on the substrate3006 in various two-dimensional arrays. In the illustrated example, thesubstrate 3006 has four substrate regions 3008 arranged in line (i.e., aone by four array). However, other configurations are possible. By wayof example, eight substrate regions 3008 can be arranged in a two byfour array. In some instances, the substrate 3006 includes at least 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16 or more substrate regions 3008.In some instances, the substrate regions 3008 are arranged in one row(e.g., a one by two, one by three, one by four array, or an array of oneby any suitable number). In some instances, the substrate regions 3008are arranged in two rows (e.g., a two by two, two by three, two by fourarray, or an array of two by any suitable number). The substrate regions3008 can be arranged in a symmetrical array (e.g., an array of two bytwo, two by three, two by four, etc.) or a non-symmetrical array (e.g.,an array that has a first number of substrate regions in a first columnand a second number (different from the first number) of substrateregions in a second column).

The gasket 3002 includes a gasket body 3012 and one or more apertures3014 defined in the gasket body 3012. The gasket 3002 is configured tobe reversibly disposed onto the substrate 3006. In some implementations,the gasket 3002 includes the same number of apertures 3014 as thesubstrate regions 3008 of the substrate 3006. Alternatively, the gasket3002 may have more or less apertures 3014 than number of the substrateregions 3008. The apertures 3014 are arranged to correspond to thesubstrate regions 3008 when the gasket 3002 is positioned on thesubstrate 3006. For example, when the gasket 3002 is disposed on thesubstrate 3006, the apertures 3014 of the gasket 3002 are aligned withthe substrate regions 3008 of the substrate 3006, respectively, therebydefining a plurality of chambers 3016, as shown in FIG. 11C. Asdescribed herein, the plurality of chambers 3016 are used as perfusionchambers for biological samples on the substrate 3006. In someembodiments, the plurality of chambers 3016 allow for independentexperiments or replicates run on one substrate 3006.

Each aperture 3014 can have at least two ports through which fluid canflow into and out from the aperture 3014. For example, the aperture 3014can include an inlet port 3018 and an outlet port 3020 as shown in FIG.11A. Conversely, the aperture 3014 can include an inlet port 3020 and anoutlet port 3018. The inlet port 3018 is configured to permit fluid toenter the aperture 3014 (or the chamber 3016 defined at least by theaperture 3014), and the outlet port 3020 is configured to permit fluidto exit the aperture 3014 (or the chamber 3016 defined at least by theaperture 3014).

The gasket 3002 further includes one or more input channels 3022 and oneor more output channels 3024. The input channels 3022 can be at leastpartially enclosed by the substrate 3006 and the cover 3004 when thegasket 3002 is sandwiched between the substrate 3006 and the cover 3004,so that fluid can flow along the input channels 3022. Similarly, theoutput channels 3024 can be at least partially enclosed by the substrate3006 and the cover 3004 when the gasket 3002 is disposed between thesubstrate 3006 and the cover 3004, so that fluid can flow along theoutput channels 3024.

The inlet ports 3018 are fluidly connected to the input channels 3022,respectively. Accordingly, the input channels 3022 are fluidly connectedto the apertures 3014 through the inlet ports 3018, respectively. Theoutlet ports 3020 are fluidly connected to the output channels 3024,respectively. Accordingly, the output channels 3024 are fluidlyconnected to the apertures 3014 through the outlet ports 3020,respectively. FIG. 11A shows the gasket 3002 can include an upstreambore 3026 and a downstream bore 3028, or vice versa. The upstream bore3026 is fluidly connected to the input channels 3022 so that the inputchannels 3022 extend commonly from the upstream bore 3026. Accordingly,the input channels 3022 extend between the upstream bore 3026 and theinlet ports 3018 of the apertures 3014, respectively. The downstreambore 3028 is fluidly connected to the output channels 3024 so that theoutput channels 3024 extend commonly from the downstream bore 3028.Accordingly, the output channels 3024 extend between the downstream bore3028 and the output ports 3020 of the apertures 3014, respectively.

Although the gasket 3002 is primarily described as having a singleupstream bore 3026 for all the input channels 3022 and a singledownstream bore 3028 for all the output channels 3024, alternativeconfigurations are possible. For example, the gasket 3002 can includemultiple upstream bores 3026, and at least one of the multiple upstreambores 3026 is fluidly connected to multiple input channels 3022.Similarly, the gasket 3002 can include multiple downstream bores 3028,and at least one of the multiple downstream bores 3028 is fluidlyconnected to multiple output channels 3024. In other examples, thegasket 3002 can include multiple upstream bores 3026 for respectiveinput channels 3022, and/or multiple downstream bores 3028 forrespective output channels 3024.

In some implementations, at least two or more of the input channels 3022have different lengths between the upstream bore 3026 and the respectiveinlet ports 3018. For example, in the illustrated example of FIG. 11A,the input channels 3022 includes first, second, third, and fourth inputchannels 3022A-3022D, and the first, second, third, and fourth inputchannels 3022A-3022D have different lengths L1-L4 that are determined asdistances of routes or paths between the upstream bore 3026 and therespective inlet ports 3018 of the apertures 3014. Alternatively or inaddition, at least two of the input channels 3022 can have the samelength between the upstream bore 3026 and the respective inlet ports3018. By way of example, the upstream bore 3026 can be positionedbetween a group of first and second apertures 3014A-B and a group ofthird and fourth apertures 3014C-D (e.g., where the upstream bore 3026is positioned along a hypothetical line that splits the two groups), andthe first and second input channels 3022A-B can have the same lengths asthe third and fourth input channels 3022C-D, respectively.

In addition or alternatively, at least two or more of the outputchannels 3024 have different lengths between the downstream bore 3028and the respective outlet ports 3020. For example, in the illustratedexample of FIG. 11A, the output channels 3024 includes first, second,third, and fourth input channels 3024A-D, and the first, second, third,and fourth input channels 3024A-D have different lengths L5-L8 that aredetermined as distances of routes or paths between the downstream bore3028 and the respective outlet ports 3020 of the apertures 3014.Alternatively or in addition, at least two of the outlet channels 3024can have the same length between the downstream bore 3028 and therespective outlet ports 3020. By way of example, the downstream bore3028 can be positioned between the group of first and second apertures3014A-B and the group of third and fourth apertures 3014C-D (e.g., wherethe downstream bore 3028 is positioned along a hypothetical line thatsplits the two groups), and the first and second output channels 3024A-Bcan have the same lengths as the third and fourth output channels3024C-D, respectively.

The upstream bore 3026 and the downstream bore 3028 can be arranged invarious positions in the gasket 3002. In some implementations, asillustrated in FIG. 11A, the upstream bore 3026 can be positioned to beopposite to the downstream bore 3028 with respect to the group of theapertures 3014. For example, the gasket 3004 has a rectangular shape ofthe gasket body 3012 with four corners 3030A-D. The upstream bore 3026can be positioned at a first corner 3030A of the gasket body 3012, andthe downstream bore 3028 can be positioned it a third corner 3030C thatis opposite to the first corner 3030A. In other implementations, theupstream bore 3026 can be positioned to be opposite to the downstreambore 3028 relative to a center C of the gasket 3002. Other positions ofthe upstream bore 3026 and the downstream bore 3028 are also possible toprovide suitable fluid stream into and out from the apertures 3014.

In some implementations, the inlet/input features (e.g., the inlet port3018, the input channels 3022, the upstream bore 3026, etc.) can bereversed with the outlet/output features (e.g., the outlet port 3020,the output channels 3024, the downstream bore 3028, etc.). For example,the outlet/output features can be used for receiving fluid and theinlet/input features can be used for discharging the fluid.

The gasket 3002 can be made of one or more various materials. The gasket3002 can be made of a material that provides appropriate seals at theinterface between the gasket 3002 and the substrate 3006, and at theinterface between the gasket 3002 and the cover 3004, so that fluidpaths are sealingly defined along the input channels 3022, the chambers3016 (defined at least by the apertures 3014), and the output channels3024 in the system 3000 without leakage between adjacent fluid paths orleakage from the system 3000 as a whole. In some implementations, thegasket 3002 can be made of silicone. Alternatively, the gasket 3002 canbe made of natural rubber, nitrile rubber, polytetrafluoroethylene(PTFE), for example. In some instances, the gasket is reversibly appliedand connected to the cover 3004 and/or the substrate 3006.

The gasket 3002 can be configured in various dimensions. In someimplementations, the gasket 3002 has a thickness T that ranges between0.1 mm and 5.0 mm. In other implementations, the thickness T of thegasket 3002 can range between 0.6 mm and 1.0 mm. In yet otherimplementations, the thickness T of the gasket 3002 can be less than 0.1mm. In yet other implementations, the thickness T of the gasket 3002 canbe greater than 5.0 mm.

The apertures 3014 of the gasket 3002 can be configured in variousdimensions. Each aperture 3014 can have an area that ranges between 40mm² and 90 mm². Each aperture 3014 can have a volume that ranges between2 mm³ and 175 mm³. The apertures 3014 can have the same area and volume.Alternatively, at least one of the apertures 3014 have a different areaor volume from the other apertures 3014.

The apertures 3014 of the gasket 3002 can be configured in variousshapes. For example, as shown in FIG. 11A, each aperture 3014 has alength L and a width W. In some implementations, the aperture 3014 canhave the width W that varies at least partially along the length L. Forexample, the aperture 3014 includes a first portion 3032 and a secondportion 3034. The first portion 3032 of the aperture 3014 includes theinlet port 3018, and the second portion 3034 of the aperture 3014includes the outlet port 3020. The first portion 3032 has a first widthW1, and the second portion has a second width W2. In someimplementations, the first width W1 of the first portion 3032 can varybetween the inlet port 3018 and the second portion 3034 (e.g., an end ofthe second portion 3034 that interfaces the inlet port 3018). Forexample, the first width W1 of the first portion 3032 can graduallyincrease from the inlet port 3018 to the interface between the firstportion 3032 and the second portion 3034, so that the first portion 3032has generally a triangular shape. In addition or alternatively, thesecond width W2 of the second portion 3034 can be consistent in thedirection of the length L. The first width W1 of the first portion 3032can be identical to the second width W2 of the second portion 3034 atthe interface between the first portion 3032 and the second portion3034.

In other examples, the aperture 3014 of the gasket 3002 can havedifferent configurations. For example, as illustrated in FIG. 17D, theaperture 3014 can be shaped as a square or rectangular that has aconsistent width along the length. Other suitable shapes, such ascircular, oval, hexagonal, etc. are also possible.

In some implementations, the gasket 3002 can include the number ofapertures 3014 that is identical to the number of the substrate regions3008 of the substrate 3006, so that the apertures 3014 are aligned withthe respective substrate regions 3008, as shown in FIGS. 11C and 17D. Inother implementations, the gasket 3002 can have the apertures 3014 lessthan the substrate regions 3008 of the substrate 3006 so that at leastone of the apertures 3014 is aligned with a plurality of substrateregions 3008. For example, as illustrated in FIGS. 17A and 17C, wherethe substrate 3006 has four substrate regions 3008, the gasket 3002 canhave two apertures 3014 that is each configured to align with two of thesubstrate regions 3008. In this configuration, fluid that is introducedinto each aperture 3014 runs through two substrate regions 3008. Inanother example, as illustrated in FIG. 17B, the gasket 3002 has asingle aperture 3014 configured to align with four substrate regions3008 of the substrate 3006, so that fluid that is introduced into theaperture 3014 is commonly supplied to all the four substrate regions3008. In yet other implementations, the gasket 3002 can have theapertures 3014 more than the substrate regions 3008 of the substrate3006 so that at least one of the substrate regions 3008 can be alignedwith two or more apertures 3014.

In some implementations, each aperture 3014 can have a single inputchannel 3022 and a single output channel 3024, as shown in FIG. 11A. Inother implementations, each aperture 3014 can have multiple inputchannels 3022 and/or multiple output channels 3024. By way of example,in FIGS. 17B-17D, each aperture 3022 has two input channels 3022.

In some implementations, the input channels 3022 and/or the outputchannels 3024 can have a consistent width along their lengths, asillustrated in FIGS. 11A and 17B-17D. In other implementations, theinput channels 3022 and/or the output channels 3024 can have variedwidths along their lengths. By way of example, as illustrated in FIG.17C, the output channels 3024 can have a width that decreases from theoutput port 3020 to the downstream bore 3028.

Referring to FIGS. 10A-10B, the cover 3004 is configured to bepositioned on the gasket 3002. For example, the cover 3004 can bemounted onto the gasket 3002 opposite to the substrate 3006, so that theplurality of chambers 3016 are defined in the system 3000.

The cover 3004 can include an inlet 3036 and an outlet 3038. The inlet3036 is positioned such that the inlet 3036 is fluidly connected to theplurality of input channels 3022 of the gasket 3002 when the cover 3004is mounted onto the gasket 3002. The inlet 3036 can be used to introducefluid into the system 3000 (e.g., into the chambers 3016 defined atleast part by the apertures 3014 of the gasket 3002). For example, theinlet 3036 can be aligned with the upstream bore 3026 of the gasket 3002when the cover 3004 is disposed on the gasket 3002.

The outlet 3038 is positioned such that the outlet 3038 is fluidlyconnected to the plurality of output channels 3024 of the gasket 3002when the cover 3004 is mounted onto the gasket 3002. The outlet 3038 canbe used to discharge fluid from the system 300 (e.g., from the chambers3016 defined at least part by the apertures 3014 of the gasket 3002).For example, the outlet 3038 can be aligned with the downstream bore3028 of the gasket 3002 when the cover 3004 is disposed on the gasket3002.

In the illustrated example, the cover 3004 includes a single inlet 3036and a single outlet 3038 for multiple chambers 3016 (FIG. 11C). In otherimplementations, the cover 3004 can have multiple inlets 3036 and/ormultiple outlets 3038 for respective ones of at least some of themultiple chambers 3016.

The cover 3004 can be made of one or more various materials. In someimplementations, the cover 3004 is made of plastic. In otherimplementations, the cover 3004 can be made of Silica glass, Quartz,Polystyrene, PLA (Poly Lactic Acid), Acrylic or Polymethyl Methacrylate(PMMA), Polycarbonate (PC), Polyethylene (PE), Polypropylene (PP),Polyethylene Terephthalate (PETE or PET), Polyvinyl Chloride (PVC),and/or Acrylonitrile-Butadiene-Styrene (ABS), or other suitablematerials.

In some implementations, as illustrated in FIGS. 10A-10B, the cover 3004is separately made and disposed on the gasket 3002. Alternatively, thecover 3004 and the gasket 3002 can be made in a single piece that can beplaced on a substrate in the same or similar way as described herein. Insome embodiments, the cover 3004 and the gasket 3002 are reversiblyplaced on the substrate, for example for removal during downstreamprocessing of the sample located in one or more of the chambers on thesubstrate.

(c) Substrates Comprising Multi-Well Plates

In some embodiments, a substrate described herein comprises a multi-wellplate and includes one or more wells, each of which is configured toreceive a biological sample. In some implementations, the multi-wellplate includes a plurality of wells for placing a plurality of samples.In some embodiments, the plurality of capture probes, as describedherein, are directly attached to the wells. For example, the captureprobes are directly printed at a surface (e.g., a bottom surface) in thewells. In some embodiments, the plurality of capture probes are attached(e.g., printed) to a substrate, e.g., a coverslip, and the substrate isplaced within the wells. In some embodiments, the coverslips are custommade to fit within the multi-well plate. In some embodiments, thecoverslip comprises plastic (e.g., polystyrene plastic), metal, glass,or any materials compatible for attachment of the capture probes. Insome embodiments, the capture probes are attached to the wells or thesubstrate chemically, e.g., via one or more linkage groups. In someembodiments, the linkage groups include amide groups, epoxides, thiol,Acrydite™. In some embodiments, the well or the substrate has additionalsurface chemistry to facilitate the growth and/or attachment of cells asknown in the art. In some embodiments, the well (e.g., a polystyrenemicroplate well) or the substrate (e.g., a polystyrene coverslip) isexposed to a plasma gas to order to modify the hydrophobic plasticsurface to make it more hydrophilic. The resulting surface carries a netnegative charge due to presence of oxygen-containing functional groups(e.g., hydroxyl and/or carboxyl groups). In some embodiments, the wellor the substrate is coated with poly-lysine and/or collagen. Details canbe found, e.g., in Curtis et al., The Journal of Cell Biology 97.5(1983): 1500-1506, which is incorporated herein by reference in itsentirety.

In some embodiments, the wells can be arranged in the multi-well platein various two-dimensional ways. For example, as illustrated in FIG. 18,a multi-well plate can have a single well; two wells arranged in line(i.e., a one by two plate); or four wells arranged in line (i.e., a oneby four plate). However, other configurations are possible. By way ofexample, eight wells can be arranged in a two by four plate. In someinstances, the multi-well plate includes at least 1, 2, 3, 4, 5, 6, 7,8, 9, 10, 12, 14, 16, 24, 48, 96, 384, or more one or more wells. Insome instances, the wells are arranged in one row (e.g., a one by two,one by three, one by four plate, or a plate of one by any suitablenumber). In some instances, the wells are arranged in two rows (e.g., atwo by two, two by three, two by four plate, or a plate of two by anysuitable number). The wells can be arranged in a symmetrical plate(e.g., a plate of two by two, two by three, two by four, etc.) or anon-symmetrical array (e.g., a plate that has a first number of wells ina first column and a second number (different from the first number) ofwells in a second column).

In some embodiments, the multi-well plate described herein is assembledby mounting a gasket comprising a plurality of apertures (e.g., any oneof the gasket described herein) onto a substrate comprising a pluralityof substrate regions (e.g., a spatial array slide). Thus, a well of theassembled multi-well plate is defined by the substrate region of thesubstrate, and the aperture of the gasket. In some embodiments, thegasket is configured to be mounted onto the substrate such that theplurality of apertures are aligned with the plurality of substrateregions, respectively. The configuration of the substrate regions andapertures of the assembled multi-well plate can be any one of theconfigurations described herein. In some embodiments, the assembledmulti-well plate is disassembled after permeabilizing the biologicalsample (e.g., a live tissue sample or cell sample), and the substrate(e.g., the spatial array slide) is subjected to spatial analysis.

In some embodiments, tissue culture dishes useful in methods disclosedherein include, but are not limited to, 35 mm, 60 mm, 100 mm, 150 mmdiameter dishes as well as flasks T-25, T-27, T-175, T-225. In someembodiments, multi will plates includes multi-layer flasks. Methodsdisclosed herein can further include microfluidic culture chips (e.g.,chips manufactured by Darwin Microfluidics, Paris, France).

In some embodiments, the multi-well plate is commercially available. Forexample, the multi-well plate described herein is a 6-well plate, an8-well plate, a 12-well plate, a 24-well plate, a 48-well plate, a96-well plate or a 384-well plate. In some embodiments, the multi-wellplate is custom made, e.g., to accommodate specific needs (e.g.,automatic detection of cellular activities or intracellular geneexpressions). In some embodiments, the multi-well plate isheat-resistant, such that the plate is compatible with one or more stepsof the spatial analysis described here (e.g., reverse transcriptionand/or PCR amplification). In some embodiments, the spatial geneexpression of tissues or cells is obtained within each individual wellof the multi-well plate. In some embodiments, the multi-well plate iscapable of automatic detection (e.g., plate-based scanning) of cellularactivity and/or the intracellular gene expression as described herein.

In some embodiments, the well or the substrate described hereincomprises one or more fiducial markers. For example, the fiducialmarkers can allow for proper orientation, detection, and/or rotation ofthe sample on the substrate. In some instances, the fiducial markersprovide a visual reference of the biological sample (e.g., one or morecells in the biological sample) in respect to the substrate.

(d) Methods of Measuring Cellular Activity

In one aspect, cellular activity of a biological sample can be recordedusing the methods as described herein. Examples of cellular activity caninclude, but are not limited to: protein activity (e.g., kinaseactivity), phosphorylation activity, G protein-coupled receptor relatedactivity, ion channel activity (e.g., switch between open and closedconformation), ligand-receptor binding activity, neural activity (e.g.,neuronal action potentials), protein synthesis (e.g., transcription ortranslation) activity, protein expression and localization (e.g.,sub-cellular organelle protein expression and trafficking), transientoptical activity (e.g., optical reporter gene expression), cell-to-cellinteraction, cellular morphology, vesicular trafficking (e.g.,exocytosis or endocytosis), protein translocation and/or proteinpost-translational modifications (e.g., ubiquitination orglycosylation). In some embodiments, the cellular activity includesprocesses in cell signaling pathways or cascades. In some embodiments,the cellular activity includes conformational changes of biomolecules(e.g., proteins or nucleic acids). In some embodiments, the cellularactivity is that which occurs upon contacting one or more cells with apharmacological compound. For example, the detection of apoptosis of oneor more cells is recorded pre and post addition of, for example, a drugthat may or may not be useful in treating cancers or other aberrantcellular proliferation diseases. As such, the methods described hereincan be used in drug discovery. Additionally, the present methods can beused to track or monitor the success or failure of a patient beingtreated with a drug or medicament, for example by tracking the presenceor absence of the desired cellular activity that is expected to occurwhen a patient is treated with the desired drug or medicament.Therefore, the present methods can be used to help determine a treatmentregimen for a patient, track or monitor the success of that treatmentduring therapy and track or monitor post therapeutic treatment successor relapse.

In some embodiments, the methods include a recording step of thebiological sample. In some instances, the biological sample is a livetissue section as described herein. In some instances, the biologicalsample is a culture of cells as described herein. The recording detectsone or more of the cellular activities disclosed herein. In someinstances, the recording step comprises optical recording. In someinstances, optical recording includes measuring of membrane potentialactivity. In some instances, optical recording captures fast(approximately 1 msec) cellular electrical activity such as ion channelactivity (e.g., switch between open and closed conformation) or neuralactivity (e.g., neuronal action potentials). In some instances, opticalrecording includes using chemical dyes or indicators. In someembodiments, the chemical dye or indicator comprises a fluorophore, suchthat the fluorescent signal, or lack thereof, can be recorded in orderto detect one or more cellular activities. In some instances, therecording step comprises electrical recording.

In some embodiments, the chemical dye is a voltage-sensitive dye, apH-sensitive dye, a temperature-sensitive dye, a light-sensitive dye, anoxygen-sensitive dye, a metal sensitive dye, or any chemical dyes thatcan be used to track one or more cellular activities as describedherein.

In some embodiments, the chemical dye is a voltage-sensitive dye.Voltage-sensitive dyes, also known as potentiometric dyes, are dyeswhich change their spectral properties in response to voltage changes.They are able to provide linear measurements of firing activity ofsingle neurons, large neuronal populations or activity of myocytes. Manyphysiological processes are accompanied by changes in cell membranepotential which can be detected with voltage sensitive dyes.Measurements may indicate the site of action potential origin, andmeasurements of action potential velocity and direction may be obtained.

In some instances, potentiometric dyes can be used to monitor theelectrical activity inside cell organelles where it is not possible toinsert an electrode, such as the mitochondria and dendritic spine. Thistechnology is powerful for the study of patterns of activity in complexmulticellular preparations. It also makes possible the measurement ofspatial and temporal variations in membrane potential along the surfaceof single cells.

In some embodiments, the voltage-sensitive dye may be contacted with thebiological sample using a contact method chosen from: intravenousinjection; intramuscular injection; intraventricular injection; spinaltap; craniotomy with direct contact of dye to cortical surface of thetissue sample (e.g., a brain tissue sample).

Non-limiting examples of suitable voltage-sensitive dyes include, butare not limited to: merocyanine-rhodamine dyes including NK 2761;minonaphthylethenylpyridinium dyes including Di-4-ANEPPS, di-8-ANEPPS,Di-2-ANEPEQ, Di-8-ANEPPQ and Di-12-ANEPPQ;dialkylaminophenylpolyenylpyridinium dyes including RH 160, RH 237, RH414, RH 421, and RH 795; oxonol dyes including RH 155, RH 482, RH 1691,RH 1692, and RH 1838; and dipicrylamine (DPA).

In some instances, the voltage-sensitive dye includes amembrane-localized voltage-sensitive protein coupled to a captureprotein. In some embodiments, the capture protein is arranged anddisposed to capture small-molecule fluorescent dyes. In someembodiments, the voltage sensitive protein is an opsin, such as, but notlimited to, a microbial opsin. Suitable microbial opsins include, butare not limited to, QuasAr2, Ace2N, or a combination thereof. In someembodiments, the voltage sensitive protein includes at least onevoltage-sensing domain selected from the group consisting of a Cionaintestinalis voltage-sensing domain (CiVSD), Danio rerio voltage-sensingdomain (DrVSD), Gallus gallus voltage-sensing domain (GgVSD), or acombination thereof. In some embodiments, a capture protein is acovalent capture protein. In one embodiment, the covalent captureprotein is selected from the group consisting of HaloTag, SNAP-tag,TMP-tag, pLac-tag, CLIP-tag, or a combination thereof. In someembodiments, the capture protein is a non-covalent capture protein. Inone embodiment, the non-covalent capture protein is selected from thegroup consisting of TMP-tag, biotin-avidin, and a combination thereof. Adetailed description can be found, e.g., in U. S. Pat. No. 10,405,750,and in PCT Application Publication No. 2018102577A1, each of which isincorporated herein by reference in its entirety.

In some embodiments, the chemical dye is a calcium-sensitive dye, e.g.,a calcium-sensitive fluorescent dye (or indicator). ImagingCa²⁺-sensitive fluorescent indicators provides a common approach forstudying Ca²⁺ signals in many contexts. Fluorescent indicators areparticularly useful for measuring acute Ca²⁺ changes in a relativelynoninvasive manner. The availability of indicators that can be targetedto specific cellular domains, coupled with variations in affinity,brightness or spectral characteristics, provides tools for exploringspatially and temporally diverse Ca²⁺ signals, and moreover,multiplexing the readout of Ca²⁺ with other cellular functions.Non-limiting examples of fluorescent indicators to monitor intracellularCa²⁺ concentration include fluorescent protein reporters such aspericams, cameleons, modified yellow cameleons (YCs), and camgaroos. TheCa²⁺ signals can also be measured with synthetic indicators such Fura-2,Indol-1, and Fluo-4. The procedures described can be applied to manyimaging modalities, including wide-field, confocal, and total internalreflection (TIRF) microscopy. It is known in the art that theexperimental details can vary depending on the cell type, imagingsystem, and characteristics of the Ca²⁺ signals being studied. Usingappropriate technology and suitable indicators, it is possible tomonitor Ca²⁺ signals spanning from subcellular to multicellular, at highspeed or time lapse, within living cells. Details can be found in, e.g.,Bootman, Martin D., et al. Cold Spring Harbor Protocols 2013.2 (2013):pdb-top066050; which is incorporated by reference in its entirety.

In some embodiments, the indicator is a genetically-encoded indicator,e.g., a genetically-encoded neural activity indicator, agenetically-encoded voltage indicator (GEVI) or a genetically-encodedcalcium indicator (GCaMP). Genetically encoded voltage indicator (orGEVI) is a protein that can sense membrane potential in a cell andrelate the change in voltage to a form of output, often fluorescentlevel. A GEVI is an optogenetic recording tool that enables exportingelectrophysiological signals from cultured cells, live animals,including the human brain. Examples of notable GEVIs include ArcLight,ASAP1, ASAP3, and Ace2N-mNeon.

GEVI can have many configuration designs in order to realize voltagesensing function. An essential feature of GEVI structure is that it mustsituate on the cell membrane. Conceptually, the structure of a GEVIshould permit the function of sensing the voltage difference andreporting it by change in fluorescence. Usually, the voltage-sensingdomain (VSD) of a GEVI spans across the membrane and is connected to thefluorescent protein(s).

In some instances, by structure, GEVIs include at least four categories:(1) GEVIs that contain a fluorescent protein FRET pair, e.g., VSFP1, (2)single opsin GEVIs, e.g., Arch, (3) opsin-FP FRET pair GEVIs, e.g.,MacQ-mCitrine, and (4) single FP with special types of voltage sensingdomains, e.g. ASAP1. In some instances, the GEVI contains a fluorescentprotein FRET pair. In some instances, the GEVI is a single opsin GEVI.In some instances, the GEVI is an opsin-FP FRET pair GEVI. In someinstances, the GEVI is a single FP with special types of voltage sensingdomains. A majority of GEVIs are based on the Ciona intestinalis voltagesensitive phosphatase (Ci-VSP or Ci-VSD (domain)). Some GEVIs might havesimilar components, but with different positioning of them. For example,ASAP1 and ArcLight both use a VSD and one FP, but the FP of ASAP1 is onthe outside of the cell whereas that of ArcLight is on the inside, andthe two FPs of VSFP-Butterfly are separated by the VSD, while the twoFPs of Mermaid are relatively close to each other. Non-limiting examplesof GEVIs include FlaSh, VSFP1, SPARC, Flare, VSFP3.1, Mermaid, hVOS,Red-shifted VSFP's, PROPS, Zahra, Zahra 2, ArcLight, Arch, ElectricPk,VSFP-Butterfly, VSFP-CR, Mermaid2, Mac GEVIs, QuasArl, QuasAr2, Archer,ASAP1, Ace GEVIs, ArcLightning, Pado, ASAP2f, FlicR1, Bongwoori, ASAP2s,ASAP-Y, (pa)QuasAr3(-s), Voltron(-ST), and/or ASAP3. Detaileddescriptions can be found, e.g., in Xu et al., Current Opinion inChemical Biology 39 (2017): 1-10; Bando et al. Cell Reports 26.3 (2019):802-813, each of which is incorporated by reference in its entirety.

In some embodiments, the genetically-encoded indicator is agenetically-encoded calcium indicator (GECI, or GCaMP). GECI provides analternative to synthetic indicators. GECIs can be easily targeted tospecific cell types or sub-cellular compartments, and are compatiblewith long-term, repeated in vivo measurements. GECIs consist of acalcium-binding domain such as calmodulin or troponin C, fused to one ormore (e.g., one, two, three, four, or more) fluorescent proteins (FPs).In single-FP GECIs, the fluorescence intensity of a circularly permutedFP (cpFP) is modulated by calcium binding-dependent changes in thechromophore environment. In two-FP GECIs and multiple-FP GECIs, calciumbinding modulates fluorescence resonance energy transfer (FRET) betweenFPs. In some embodiments, GECIs are useful for screening for agonists orantagonists of G-protein coupled receptor (GPCR) or ion channels andmonitoring neural activity. As a non-limiting example, intracellularcalcium level changes induced by G-protein coupled receptor activationcan be indicated by fluorescent signal changes emitted by GAcMP.Additional description can be found. e.g., in U.S. Pat. No. 9,518,980B2, which is incorporated by reference in its entirety.

In some embodiments, the indicator discriminates between live and deadcells. For example, vitality dyes such as LIVE-OR-DYE dead cell dyes arecell membrane impermeable and amine-reactive. Such vitality stains canenter cells with damaged cell membranes, label intracellular proteins,and exhibit high levels of fluorescence. These vitality dyes can alsoreact to cell surface proteins, however because cell surface proteinsare less abundant than intracellular proteins the fluorescenceassociated with live cells is very low. Additional indicators includenon-fluorescent dyes that only fluorescence when they enter cells suchas live cell labeling or tracking dyes and cell proliferation dyes, forexample Cytopainter live cell dyes are hydrophobic compounds thatpermeate across cell membranes and become highly fluorescent once insidethe cell.

In some instances, the step of recording one or more cellular activitiesincludes imaging the biological sample. In some instances, the sample isrecorded before the sample is provided with one or more dyes orindicators. In some instances, the sample is recorded at the same timeas when the sample is provided with one or more dyes or indicators. Insome instances, the sample is recorded after the sample is provided withone or more dyes or indicators. In some instances, the sample isrecorded before, during and/or after the sample is provided with one ormore dyes or indicators. In some embodiments, temporal formation ofcellular activities can be assessed using the methods described herein.For example, temporal (e.g., real-time) formation of the target cellularactivity can be recorded by detecting and measuring the cellularactivity (e.g., using dyes) by a fluorescent time lapse microscopy.Imaging can be performed using any of the microscopy techniquesdescribed herein. In some instances, imaging is performed usingfluorescence microscopy, fluorescent time lapse microscopy, confocalmicroscopy, multi-photon microscopy (e.g., two-photon excitationmicroscopy), or any known microscopy techniques known in the art.

In some instances, after recording cellular activity, the sample isfixed. In some instances, the analytes in the sample can hybridize to aplurality of probes on an array (e.g., substrate) as described herein.In some instances, the poly-adenylation (poly(A)) sequence of an mRNAhybridizes to a poly-thymine (poly(T)) capture domain sequence on acapture probe. In some instances, the capture probe is extended usingthe analyte that is specifically bound to the capture domain as atemplate to generate an extended capture probe. In some instances, theextended capture probe is amplified to produce a plurality of extendedcapture probes. In some instances, the plurality of extended captureprobes, or libraries created therefrom, is sequenced. In some instances,all or a portion of the sequence of the spatial barcode, or a complementthereof, is determined. In some instances, all or a portion of thesequence of the analyte, or a complement thereof, is determined. In someinstances, the determined sequences are used to identify the location ofthe analyte in the biological sample.

(e) Methods of Measuring Gene Expression

In some embodiments, intracellular gene expression of a nucleic acid ofa biological sample can be recorded using the methods as describedherein. In some embodiments, the method involves multiple molecular dyesattached to a single probe (e.g., a probe that can hybridize to a targetnucleic acid) for increased signal-to-noise ratio. In some embodiments,dual probes containing split fluorescent proteins are used. In someembodiments, Forster resonance energy transfer (FRET) based signalgeneration is used. In some embodiments, fluorescent quenching can occurwhen the probe binds to the target nucleic acid to restrict signal. Insome embodiments, the probe contains fluorescent nucleotides. Detailscan be found, e.g., in Wu et al., Chemical Science 11.1 (2020): 62-69;Spille and Ulrich, Journal of Cell Science 128.20 (2015): 3695-3706,each of which is incorporated by reference in its entirety. In someembodiments, the nucleic acid described herein (e.g., an RNA) can bevisualized in vivo. In some embodiments, the nucleic acid describedherein (e.g., an RNA) can be visualized in vitro.

In some embodiments, the intracellular gene expression can be recordedoptically through the use of in situ hybridization (e.g., fluorescent insitu hybridization (FISH)). The objective of in situ hybridization is todetermine the presence or absence of one or more nucleic acid sequencesof interest at particular spatial locations in a cell or chromosomalsites. Particular nucleic acid sequences are identified within cells bytaking advantage of a property of nucleic acids (i.e., their ability tospecifically anneal to each other to form hybrids). This process can beused to hybridize two complementary strands of DNA, one strand of RNA toone strand of DNA, and two complementary strands of RNA. In someinstances, strand hybridization occurs between natural and artificialnucleic acids. Thus, in some instances, gene expression detectionexamines a particular transcript of interest.

In some instances, the transcript is associated with normal physiology.In some instances, the transcript is associated with a pathophysiology(e.g., cancer or aberrant development or other disease state). In someinstances, a FISH probe is designed to detect one or more mutations. Forexample, and without limitation, a FISH probe can be designed to detecta point mutation, a single nucleotide polymorphism, an insertion, adeletion, and/or a translocation. In some instances, the probe isdesigned to detect one or more exons in an mRNA analyte that isalternatively spliced.

In some instances, the probe is directly labeled with a detectablemarker as disclosed herein. In some instances, the detectable marker isa fluorescent, radioactive, chemiluminescent, or colorimetric detectablemarker. In some instances, the probe is not directly labeled with adetectable marker. In this instance, a second moiety (e.g., comprising afluorophore) is associated with the hybridized complementary nucleicacids. In some instances, the second moiety includes a fluorescent,radioactive, chemiluminescent, or colorimetric detectable marker.

After a nucleic acid probe is annealed to complementary sequences incells or tissue, the hybridized probe is visualized. When one of the twostrands is labeled, the annealed hybrids can be detected by variousmethods, including isotopic and nonisotopic (fluorescent andnonfluorescent) approaches. Additional description is found at e.g.,Jensen, The Anatomical Record 297.8 (2014): 1349-1353, which isincorporated by reference in its entirety.

In some embodiments, the intracellular gene expression can be assessedoptically through the use of fluorescence resonance energy transfer (orForster resonance energy transfer, FRET). The technique of FRET whenapplied to optical microscopy, permits determination of the approachbetween two molecules within a distance (several nanometers (e.g., 10nm)) sufficiently close for molecular interactions to occur. Themechanism of fluorescence resonance energy transfer involves a donorfluorophore in an excited electronic state, which may transfer itsexcitation energy to a nearby acceptor fluorophore in a non-radiativefashion through long-range dipole-dipole interactions. For example,nucleotide incorporations can be detected through FRET, as described forexample in Levene et al., Science (2003), 299, 682-686, Lundquist etal., Opt. Lett. (2008), 33, 1026-1028, and Korlach et al., Proc. Natl.Acad. Sci. USA (2008), 105, 1176-1181, each of which is incorporated byreference in its entirety.

In some embodiments, the recording step comprises hybridizing aplurality of optically-labelled probes to a target nucleic acid. In someembodiments, the optically-labelled probes comprise an optical label,e.g., a fluorophore. In some embodiments, the optically-labelled probesare fluorescently-labelled probes, e.g., fluorescently labelled peptidenucleic acid (PNA) probes. PNAs are synthetic nucleic acid (e.g., DNA)analogs in which the phosphodiester backbone is replaced by repetitiveunits of N-(2-aminoethyl) glycine to which the purine and pyrimidinebases are attached via a methyl carbonyl linker. The procedures for PNAsynthesis are similar to those employed for peptide synthesis, usingstandard solid-phase manual or automated synthesis. In some instances,the PNA molecules are labelled with biotin or fluorophores. Thus, insome instances, the PNA molecule disclosed herein includes a detectionmoiety such as a fluorescent, radioactive, chemiluminescent, orcolorimetric detectable marker. In some instances, the PNA molecule isassociate with (e.g., conjugated to) a biotin molecule that can bedetected using e.g., an avidin or streptavidin pulldown, as disclosedherein. A subsequent generation of PNAs involve modification of theN-(2-aminoethyl) glycine backbone (PNA analogs) or chimericarchitecture, like PNA-peptide chimeras or PNA-DNA chimeras developed inorder to improve the solubility and the cellular uptake of PNAs or toexhibit new biological properties. The synthetic backbone provides PNAwith unique hybridization characteristics. Unlike DNA and RNA, the PNAbackbone is not charged. Consequently, there is no electrostaticrepulsion when PNAs hybridize to its target nucleic acid sequence,giving a higher stability to the PNA-DNA or PNA-RNA duplexes than thenatural homo- or heteroduplexes. This greater stability is reflected bya higher thermal melting temperature (Tm), as compared to thecorresponding DNA-DNA or DNA-RNA duplexes. Detailed description can befound, e.g., in Pellestor and Paulasova, European Journal of HumanGenetics, 12.9 (2004): 694-700, which is incorporated by reference inits entirety.

In some embodiments, the optically-labelled probes (e.g., fluorescentlylabelled PNA probes) can bind to a target nucleic acid in the biologicalsample. In some embodiments, the target nucleic acid is a DNA. In someinstances, the target DNA has been denatured. In some embodiments, thetarget nucleic acid is an RNA. In some embodiments, the target nucleicacid is a single-stranded DNA or RNA. In some embodiments, the targetnucleic acid is a double-stranded DNA or double-stranded RNA. In someembodiments, the target nucleic acid is a DNA/RNA duplex. In someembodiments, the target nucleic acid is an mRNA, a siRNA, a microRNA, ora derivative thereof.

In some embodiments, the optically-labelled probe (e.g., a fluorescentlylabelled PNA probe) has at least 10, at least 11, at least 12, at least13, at least 14, at least 15, at least 16, at least 17, at least 18, atleast 19, at least 20, at least 21, at least 22, at least 23, at least24, at least 25, at least 26, at least 27, at least 28, at least 29, orat least 30 nucleic acids.

In some embodiments, the optically-labelled probe (e.g., a fluorescentlylabelled PNA probe) can be used at a final concentration of at least orabout 0.1×10⁻⁶ M, at least or about 0.5×10⁻⁶ M, at least or about 1×10⁻⁶M, at least or about 2×10⁻⁶ M, at least or about 3×10⁻⁶ M, at least orabout 4×10⁻⁶ M, at least or about 5×10′ M, at least or about 10×10⁻⁶ M,at least or about 20×10⁻⁶ M, at least or about 50×10⁻⁶M, at least orabout 100×10⁻⁶ M, or higher.

In some embodiments, one or more (e.g., 1, 2, 3, 4, or more)optically-labelled probes can hybridize to different portions of thetarget nucleic acid. In some embodiments, one or more (e.g., 1, 2, 3, 4,or more) optically-labelled probes are used for the detection of thetarget nucleic acid with a duplex structure, in which case each probehybridizes specifically to either the sense or antisense strand of thetarget nucleic acid. In some embodiments, the optical label can bedirectly detectable by itself (e.g., radioisotope labels or fluorescentlabels) or, in the case of an enzymatic label, can be indirectlydetectable, e.g., by catalyzing chemical alterations of a chemicalsubstrate compound or composition, which chemical substrate compound orcomposition is directly detectable. Optical labels can be suitable forsmall scale detection and/or suitable for high-throughput screening. Assuch, suitable optical labels include, but are not limited to,radioisotopes, fluorophores, chemiluminescent compounds, bioluminescentcompounds, and dyes.

The optical label can be qualitatively detected (e.g., optically orspectrally), or it can be quantified. Qualitative detection generallyincludes a detection method in which the existence or presence of theoptical label is confirmed, whereas quantifiable detection generallyincludes a detection method having a quantifiable (e.g., numericallyreportable) value such as an intensity, duration, polarization, and/orother properties.

In some embodiments, the optically-labelled probes comprise one or moreoptical labels, 1, 2, 3, 4, or more. For example, optical labels can beincorporated during nucleic acid polymerization or amplification (e.g.,Cy5®-labelled nucleotides, such as Cy5®-dCTP). Any suitable opticallabel can be used. In some embodiments, the optical label is afluorophore. For example, the fluorophore can be from a group thatincludes: 7-AAD (7-Aminoactinomycin D), Acridine Orange (+DNA), AcridineOrange (+RNA), Alexa Fluor® 350, Alexa Fluor® 430, Alexa Fluor® 488,Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 555, Alexa Fluor® 568,Alexa Fluor® 594, Alexa Fluor® 633, Alexa Fluor® 647, Alexa Fluor® 660,Alexa Fluor® 680, Alexa Fluor® 700, Alexa Fluor® 750, Allophycocyanin(APC), AMCA/AMCA-X, 7-Aminoactinomycin D (7-AAD),7-Amino-4-methylcoumarin, 6-Aminoquinoline, Aniline Blue, ANS, APC-Cy7,ATTO-TAG™ CBQCA, ATTO-TAG™ FQ, Auramine 0-Feulgen, BCECF (high pH), BFP(Blue Fluorescent Protein), BFP/GFP FRET, BOBO™-1/BO-PRO™-1,BOBO™-3/BO-PRO™-3, BODIPY® FL, BODIPY® TMR, BODIPY® TR-X, BODIPY®530/550, BODIPY® 558/568, BODIPY® 564/570, BODIPY® 581/591, BODIPY®630/650-X, BODIPY® 650-665-X, BTC, Calcein, Calcein Blue, CalciumCrimson™, Calcium Green-1™, Calcium Orange™, Calcofluor® White,5-Carboxyfluoroscein (5-FAM), 5-Carboxynaphthofluoroscein,6-Carboxyrhodamine 6G, 5-Carboxytetramethylrhodamine (5-TAMRA),Carboxy-X-rhodamine (5-ROX), Cascade Blue®, Cascade Yellow™, CCF2(GeneBLAzer™), CFP (Cyan Fluorescent Protein), CFP/YFP FRET, ChromomycinA3, Cl-NERF (low pH), CPM, 6-CR 6G, CTC Formazan, Cy2®, Cy3®, Cy3.5®,Cy5®, Cy5.5®, Cy7®, Cychrome (PE-Cy5), Dansylamine, Dansyl cadaverine,Dansylchloride, DAPI, Dapoxyl, DCFH, DHR, DiA (4-Di-16-ASP), DiD(Di1C18(5)), DIDS, Dil (Di1C18(3)), DiO (DiOC18(3)), DiR (Di1C18(7)),Di-4 ANEPPS, Di-8 ANEPPS, DM-NERF (4.5-6.5 pH), DsRed (Red FluorescentProtein), EBFP, ECFP, EGFP, ELF® -97 alcohol, Eosin, Erythrosin,Ethidium bromide, Ethidium homodimer-1 (EthD-1), Europium (III)Chloride, 5-FAM (5-Carboxyfluorescein), Fast Blue, Fluorescein-dTphosphoramidite, FITC, Fluo-3, Fluo-4, FluorX®, Fluoro-Gold™ (high pH),Fluoro-Gold™ (low pH), Fluoro-Jade, FM® 1-43, Fura-2 (high calcium),Fura-2/BCECF, Fura Red™ (high calcium), Fura Red™/Fluo-3, GeneBLAzer™(CCF2), GFP Red Shifted (rsGFP), GFP Wild Type, GFP/BFP FRET, GFP/DsRedFRET, Hoechst 33342 & 33258, 7-Hydroxy-4-methylcoumarin (pH 9), 1,5IAEDANS, Indo-1 (high calcium), Indo-1 (low calcium),Indodicarbocyanine, Indotricarbocyanine, JC-1, 6-JOE, JOJO™-1/JO-PRO™-1,LDS 751 (+DNA), LDS 751 (+RNA), LOLO™-1/LO-PRO™-1, Lucifer Yellow,LysoSensor™ Blue (pH 5), LysoSensor™ Green (pH 5), LysoSensor™Yellow/Blue (pH 4.2), LysoTracker® Green, LysoTracker® Red, LysoTracker®Yellow, Mag-Fura-2, Mag-Indo-1, Magnesium Green™ Marina Blue®,4-Methylumbelliferone, Mithramycin, MitoTracker® Green, MitoTracker®Orange, MitoTracker® Red, NBD (amine), Nile Red, Oregon Green® 488,Oregon Green® 500, Oregon Green® 514, Pacific Blue, PBF1, PE(R-phycoerythrin), PE-Cy5, PE-Cy7, PE-Texas Red, PerCP (Peridininchlorphyll protein), PerCP-Cy5.5 (TruRed), PharRed (APC-Cy7),C-phycocyanin, R-phycocyanin, R-phycoerythrin (PE), PI (PropidiumIodide), PKH26, PKH67, POPO™-1/PO-PRO™-1, POPO™-3/PO-PRO™-3, PropidiumIodide (PI), PyMPO, Pyrene, Pyronin Y, Quantam Red (PE-Cy5), QuinacrineMustard, R670 (PE-Cy5), Red 613 (PE-Texas Red), Red Fluorescent Protein(DsRed), Resorufin, RH 414, Rhod-2, Rhodamine B, Rhodamine Green™,Rhodamine Red™, Rhodamine Phalloidin, Rhodamine 110, Rhodamine 123,5-ROX (carboxy-X-rhodamine), S65A, S65C, S65L, S65T, SBFI, SITS,SNAFL®-1 (high pH), SNAFL®-2, SNARF®-1 (high pH), SNARF®-1 (low pH),Sodium Green™, SpectrumAqua®, SpectrumGreen® #1, SpectrumGreen® #2,SpectrumOrange®, SpectrumRed®, SYTO® 11, SYTO® 13, SYTO® 17, SYTO® 45,SYTOX® Blue, SYTOX® Green, SYTOX® Orange, 5-TAMRA(5-Carboxytetramethylrhodamine), Tetramethylrhodamine (TRITC), TexasRed®/Texas Red®-X, Texas Red®-X (NHS Ester), Thiadicarbocyanine,Thiazole Orange, TOTO®-1/TO-PRO®-1, TOTO®-3/TO-PRO®-3, TO-PRO®-5,Tri-color (PE-Cy5), TRITC (Tetramethylrhodamine), TruRed (PerCP-Cy5.5),WW 781, X-Rhodamine (XRITC), Y66F, Y66H, Y66W, YFP (Yellow FluorescentProtein), YOYO®-1/YO-PRO®-1, YOYO®-3/YO-PRO®-3, 6-FAM (Fluorescein),6-FAM (NHS Ester), 6-FAM (Azide), HEX, TAMRA (NHS Ester), Yakima Yellow,MAX, TET, TEX615, ATTO 488, ATTO 532, ATTO 550, ATTO 565, ATTO Rho101,ATTO 590, ATTO 633, ATTO 647N, TYE 563, TYE 665, TYE 705, 5′ IRDye® 700,5′ IRDye® 800, 5′ IRDye® 800CW (NHS Ester), WellRED D4 Dye, WellRED D3Dye, WellRED D2 Dye, Lightcycler® 640 (NHS Ester), and Dy 750 (NHSEster).

As discussed herein, in some embodiments, an optical label is orincludes a luminescent or chemiluminescent moiety. Commonluminescent/chemiluminescent moieties include, but are not limited to,peroxidases such as horseradish peroxidase (HRP), soybean peroxidase(SP), alkaline phosphatase, and luciferase. These protein moieties cancatalyze chemiluminescent reactions given the appropriate chemicalsubstrates (e.g., an oxidizing reagent plus a chemiluminescentcompound). A number of compound families are known to providechemiluminescence under a variety of conditions. Non-limiting examplesof chemiluminescent compound families include2,3-dihydro-1,4-phthalazinedione luminol, 5-amino-6,7,8-trimethoxy- andthe dimethylamino[ca]benz analog. These compounds can luminesce in thepresence of alkaline hydrogen peroxide or calcium hypochlorite and base.Other examples of chemiluminescent compound families include, e.g.,2,4,5-triphenylimidazoles, para-dimethylamino and -methoxy substituents,oxalates such as oxalyl active esters, p-nitrophenyl, N-alkyl acridinumesters, luciferins, lucigenins, or acridinium esters.

In some embodiments, temporal formation of specific transcripts can beassessed using the methods described herein. For example, one or morefluorescently labelled PNA probes (e.g., a first probe labelled with adonor fluorophore and a second probe labelled with an acceptorfluorophore) can hybridize to different portions (e.g., two adjacentsequences) of a target transcript. Temporal (e.g., real-time) formationof the target transcript can be recorded by measuring the excitationstatus of the acceptor fluorophore during an appropriate time period,e.g., by fluorescent time lapse microscopy. The donor and acceptorfluorophores can be any FRET pairs known in the art, as described inBajar et al., Sensors 16.9 (2016): 1488, which is incorporated byreference in its entirety.

In some embodiments, the cellular activity as described above can bemeasured at the same time or using the same sample as a sample in whichgene expression is recorded. In some instances, a cellular activity isassociated with one biomarker (e.g., one fluorescent color) and geneexpression (e.g., detection of a particular gene) is associated with asecond biomarker (e.g., a different fluorescent marker). In someinstances, both cellular activity and gene expression can be recordedoptically using fluorescence microscopy, fluorescent time lapsemicroscopy, confocal microscopy, multi-photon microscopy (e.g.,two-photon excitation microscopy), total internal reflection microscopy,super-resolution microscopy, or any known microscopy techniques known inthe art.

In some embodiments, the cellular activity and gene expression can berecorded simultaneously, e.g., by using one or more optical labels(e.g., fluorophores) to tag the chemical dyes, indicators, oroptically-labelled probes, such that the cellular activity and the geneexpression can be recorded with minimal cross-interferences.

In some instances, after recording gene expression, the sample is fixed.In some instances, the analytes in the sample can hybridize to aplurality of probes on an array (e.g., substrate) as described herein.In some instances, the poly-adenylation (poly(A)) sequence of an mRNAhybridizes to a poly-thymine (poly(T)) sequence of a capture domain on acapture probe. In some instances, the capture probe is extended usingthe analyte that is specifically bound to the capture domain as atemplate to generate an extended capture probe. In some instances, theextended capture probe is amplified to produce a plurality of extendedcapture probes (e.g., a plurality of nucleic acids). In some instances,the plurality of extended capture probes, or libraries createdtherefrom, is sequenced. In some instances, all or a portion of thesequence of the spatial barcode, or a complement thereof, is determined.In some instances, all or a portion of the sequence of the analyte, or acomplement thereof, is determined. In some instances, the determinedsequences are used to identify the location of the analyte in thebiological sample.

(f) Methods of using the Perfusion Chamber and the Multi-Well Plate

Culturing the Biological Sample

In some embodiments, the methods described herein include culturing thebiological sample in the perfusion chamber or the multi-well plate. Insome embodiments, the biological sample is cultured in a culture mediumto maintain its viability. In some embodiments, the culture medium isreplaced at an appropriate interval (e.g., about every 12 hours, aboutevery day, about every 2 days, about every 3 days, about every 4 days,about every 5 days, about every 6 days, or about every week). In someembodiments, the culture medium is replaced manually (e.g., bypipetting) or automatically. In some embodiments, the biological sampleis cultured statically. In some embodiments, the biological sample iscultured in a perfusion chamber with inlets and outlets as describedherein. In some embodiments, the culture medium is perfused to theperfusion chamber at a constant flow rate. In some embodiments, aculture medium (e.g., a tissue or cell culture medium, saline,artificial cerebral spinal fluid (ACSF)) can be perfused to theperfusion chamber to maintain viability of the biological sample (e.g.,a tissue or cell sample).

In some embodiments, the culture medium is oxygenated. In someembodiments, additional nutrients or compounds are supplemented to theculture medium to maintain viability of the biological sample. In someembodiments the culture medium includes the blocking reagent describedherein. In some instances, the blocking reagent can prevent molecule(e.g., the test compounds or drugs described herein) or cell (e.g., livecells) adhesion to the capture probes. In some embodiments, the blockingreagent is bovine serum albumin (BSA), serum, gelatin (e.g., fishgelatin), milk (e.g., non-fat dry milk), casein, polyethylene glycol(PEG), polyvinyl alcohol (PVA), or polyvinylpyrrolidone (PVP), biotinblocking reagent, a peroxidase blocking reagent, levamisole, Carnoy'ssolution, glycine, lysine, sodium borohydride, pontamine sky blue, SudanBlack, trypan blue, FITC blocking agent, acetic acid, and/oroligonucleotides including a complementary sequence to the captureoligos.

In some embodiments, the live tissues or cells are cultured in theperfusion chamber or the multi-well plate described herein and grownunder conditions to maintain cell viability. For example, temperaturesand CO2 concentrations for growing tissues and cells are well known inthe art and the methods disclosed herein practice those conditions tomaintain sample viability. In some embodiments, tissue cultureincubators are utilized during growth and perfusion of the live tissuesor cells, typical conditions to maintain cell viability being, forexample, 37° C. and 5% CO₂.

In some embodiments, chemical dyes, indicators, or optically-labelledprobes as described herein can be added to the culture medium, andperfused to the perfusion chamber (or added to the multi-well plate) tointeract with the biological sample. In some embodiments, the chemicaldyes, indicators, or optically-labelled probes can be added to thebiological sample before placing the biological sample into theperfusion chamber or the multi-well plate. In some embodiments, thechemical dyes, indicators, or optically-labelled probes can be added tothe biological sample after placing the biological sample to theperfusion chamber or the multi-well plate. In some embodiments, thechemical dyes, indicators, or optically-labelled probes can beinternalized to the cells (e.g., cells from a live tissue section) byelectropermeabilization, endocytic internalization, or lipid-basedpermeabilization, while maintaining cell viability.

In some embodiments, the methods described herein can be used to measuredynamic transcriptional FRET imaging. In some embodiments, the methodsdescribed herein can be used for real-time transcript detection duringpharmacological treatment.

In some embodiments, the biological sample (e.g., cells from a cellculture) is grown or cultured on a substrate (or a surface) within aperfusion chamber or a well of a multi-well plate. In some embodiments,the capture probes described herein are directly printed on thesubstrate (or the surface). In some embodiments, the existence ofcapture probes on the substrate (or the surface) does not affect growthof the biological sample. In some embodiments, growth or culturing ofthe biological sample on the substrate with attached capture probes doesnot affect data quality of the spatial analysis, e.g., spatial UMI andgene plots; sequencing saturation; median genes per cells; median countsper cell; or median UMIs per cell.

(ii) Live Cell Labelling

In some embodiments, the methods described herein comprise labelling aplurality of live cells of the biological sample. In some embodiments,the live cells are labelled by staining. In some embodiments, the livecells are stained by immunofluorescence (IF). In some embodiments, thelive cells are stained intracellularly (e.g., by staining a sub-cellularorganelle including endoplasmic reticulum (ER), Golgi, lysosome,mitochondria, and/or nucleus). In some embodiments, the live cells arestained extracellularly (e.g., plasma membrane staining).

In some embodiments, the live cells are labelled by a fluorescentlylabelled antibody or antibody fragments thereof. In some embodiments,the live cells are labelled by the chemical dyes, indicators, oroptically-labelled probes described herein. In some embodiments, thelive cells are labelled by fluorescent reporters (e.g., the live cellsare transfected to include a reporter gene). In some embodiments, thestained live cells are detected (e.g., recorded) by time-lapsefluorescence microscopy.

In some embodiments, the live cells are treated with proteinase K and/ortrypsin. For example, the treatment can facilitate entry (e.g., byabsorption or endocytosis) of the fluorescently labelled antibody orfragments thereof.

(iii) Blocking Probes

In some embodiments, capture probes are blocked prior to contacting thebiological sample with the substrate. In some embodiments, capturedomains of the capture probes are blocked by blocking probes. In someinstances, the capture probes are blocked to prevent molecule (e.g., thetest compounds or drugs described herein) or cell (e.g., live cells)adhesion.

In some embodiments, the blocking probe is used to block or modify thefree 3′ end of the capture domain. In some embodiments, blocking probescan be hybridized to the capture probes to mask the free 3′ end of thecapture domain, e.g., hairpin probes, partially double stranded probes,or complementary sequences. In some embodiments, the free 3′ end of thecapture domain can be blocked by chemical modification, e.g., additionof an azidomethyl group as a chemically reversible capping moiety suchthat the capture probes do not include a free 3′ end. Blocking ormodifying the capture probes, particularly at the free 3′ end of thecapture domain, prior to contacting the biological sample with thesubstrate, prevents modification of the capture probes, e.g., preventsthe addition of a poly(A) tail to the free 3′ end of the capture probes.In some embodiments, blocking the capture domain reduces non-specificbackground staining. In some embodiments, the blocking probes arereversible, such that the blocking probes can be removed from thecapture domains during or after the time that the capture domains are incontact with the biological sample. In some embodiments, the blockingprobe can be removing with RNAse treatment (e.g., RNAse H treatment).

(iv) Fixation

In some embodiments, the biological sample (e.g., a live tissue sampleor cell sample) can be fixed in any of a variety of fixatives topreserve the biological structure of the sample prior to analysis. Forexample, a sample can be fixed via immersion in ethanol, methanol,acetone, formaldehyde (e.g., 2% formaldehyde), paraformaldehyde-Triton,glutaraldehyde, or combinations thereof. In some instances, thebiological sample is fixed after recording cellular activity. In someinstances, the biological sample is fixed after recording geneexpression. In some instances, the biological sample is fixed afterrecording cellular activity and gene expression. In some embodiments,after fixation, the perfusion chamber can be disassembled such that thesubstrate (e.g., a spatial array) can be subjected to the spatialanalysis as described herein. In some embodiments, the multi-well plateis directly subjected to the spatial analysis, or the individualsubstrate (e.g., one or more coverslips) can be transferred to a properplatform (e.g., a slide), either manually or automatically, for thespatial analysis. In some embodiments, the biological sample can befixed during the recording step, followed by the spatial analysis asdescribed herein. In some embodiments, two or more fractions of thebiological sample, located in separate perfusion chambers, can be fixedat different time points during the recording step.

In some embodiments, the biological sample is fixed during test compound(e.g. drug) treatment. For example, two or more fractions of thebiological sample, each located in separate perfusion chambers (ormulti-well plates), can be fixed at different time points during testcompound (e.g., drug) treatment. In some embodiments, the biologicalsample is fixed after test compound (e.g., drug) treatment, thensubjected to the spatial analysis as described herein. In someembodiments, one or more steps (e.g., extension of capture probes byreverse transcription) of the spatial analysis are carried out directlyin the multi-well plate. For example, the multiple-well plate describedherein can be custom made (e.g., heat-resistant), thereby to becompatible with the spatial analysis steps.

(g) Methods for test compound treatment or drug screening

In some embodiments, the methods described herein comprise perfusing oneor more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) test compoundsthrough the perfusion chamber. In some embodiments, the test compoundscomprises one or more drugs. In some embodiments, one or more testcompounds can be perfused through the perfusion chamber, beforerecording the cellular activity or gene expression as described herein.In some embodiments, one or more test compounds can be perfused throughthe perfusion chamber, at substantially the same time (e.g.,simultaneously) of recording the cellular activity or gene expression asdescribed herein. In some embodiments, the perfusion and recording areautomatically performed for high-throughput screening of test compounds(e.g., drugs). In some embodiments, real-time cellular activity or geneexpression changes are recorded immediately following perfusion of thetest compounds. In some embodiments, culture medium (e.g., without anytest compounds) is perfused to remove a test compound from the perfusionchamber, followed by perfusion of the same or a different test compound.In some embodiments, the methods described herein comprise treating abiological sample with one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,or more) test compounds within a multi-well plate or a chamberedsubstrate. In some embodiments, the test compounds comprises one or moredrugs. In some embodiments, the test compounds are added to themulti-well plate or chambered substrate manually (e.g., by pipetting) orautomatically. In some embodiments, one or more test compounds are addedto the multi-well plate or chambered substrate before recording thecellular activity or gene expression as described herein. In someembodiments, one or more test compounds are added to the multi-wellplate or chambered substrate at substantially the same time (e.g.,simultaneously) of recording the cellular activity or gene expression asdescribed herein. In some embodiments, the test compound treatmentand/or the recording of the cellular activity or gene expression areautomatically performed for high-throughput screening of test compounds(e.g., drugs). In some embodiments, real-time cellular activity or geneexpression changes are recorded immediately following treatment of thetest compounds. In some embodiments, a test compound is removed (e.g.,by pipetting), followed by addition of the same or a different testcompound.

In some embodiments, the test compounds are pre-mixed and perfused tothe perfusion chamber (or added to the multi-well plate) at the sametime. In some embodiments, the test compounds are sequentially perfusedor added. In some embodiments, one or more test compounds are perfused(or added) repeatedly to induce a cellular activity or gene expressionchange. In some embodiments, the biological sample is treated with oneor more test compounds (e.g., drugs) at substantially the same time. Insome embodiments, the biological sample is treated with one or more testcompounds (e.g., drugs) at different times.

In some embodiments, the test compound (e.g., a drug) can be an agonist.In some embodiments, the test compound (e.g., a drug) can be anantagonist. In some embodiments, the test compound can be a drug, e.g.,a small-molecule drug, an antibody or antigen-binding fragment thereof,a pharmacological agent, or any test compounds of interest. In someembodiments, the test compound (e.g., a drug) activates or stimulatesone or more cellular activities. In some embodiments, the test compound(e.g., a drug) inhibits one or more cellular activities. In someembodiments, the test compound (e.g., a drug) increases intracellulargene expression of a nucleic acid. In some embodiments, the testcompound (e.g., a drug) decreases intracellular gene expression of anucleic acid. In some embodiments, the test compound (e.g., a drug)decreases the viability and thus gene expression or other cellularactivity within a cell or tissue.

In some embodiments, the test compound is an anti-cancer drug. As usedherein, the term “cancer” refers to cells having the capacity forautonomous growth, i.e., an abnormal state or condition characterized byrapidly proliferating cell growth. The term is meant to include alltypes of cancerous growths or oncogenic processes, metastatic tissues ormalignantly transformed cells, tissues, or organs, irrespective ofhistopathologic type or stage of invasiveness. Cancers described hereininclude malignancies of the various organ systems, such as affectinglung, breast, thyroid, lymphoid, gastrointestinal, and genito-urinarytract, as well as adenocarcinomas which include malignancies such asmost colon cancers, renal-cell carcinoma, prostate cancer and/ortesticular tumors, non-small cell carcinoma of the lung, cancer of thesmall intestine and cancer of the esophagus. In some embodiments, thetest compounds described herein are designed for treating or diagnosinga carcinoma in a subject. The term “carcinoma” is art recognized andrefers to malignancies of epithelial or endocrine tissues includingrespiratory system carcinomas, gastrointestinal system carcinomas,genitourinary system carcinomas, testicular carcinomas, breastcarcinomas, prostatic carcinomas, endocrine system carcinomas, andmelanomas. In some embodiments, the cancer is renal carcinoma ormelanoma. Exemplary carcinomas include those forming from tissue of thecervix, lung, prostate, breast, head and neck, colon and ovary. The termalso includes carcinosarcomas, e.g., which include malignant tumorscomposed of carcinomatous and sarcomatous tissues. An “adenocarcinoma”refers to a carcinoma derived from glandular tissue or in which thetumor cells form recognizable glandular structures. The term “sarcoma”is art recognized and refers to malignant tumors of mesenchymalderivation.

In some embodiments, the test compound is an antibody or antigen-bindingfragment thereof, e.g., Muromonab-CD3, Efalizumab, Tositumomab-I131,Nebacumab, Edrecolomab, Catumaxomab, Daclizumab, Abciximab, Rituximab,Basiliximab, Palivizumab, Infliximab, Trastuzumab, Adalimumab,Ibritumomab tiuxetan, Omalizumab, Cetuximab, Bevacizumab, Natalizumab,Panitumumab, Ranibizumab, Eculizumab, Certolizumab pegol, Ustekinumab,Canakinumab, Golimumab, Ofatumumab, Tocilizumab, Denosumab, Belimumab,Ipilimumab, Brentuximab vedotin, Pertuzumab, Ado-trastuzumab emtansine,Raxibacumab, Obinutuzumab, Siltuximab, Ramucirumab, Vedolizumab,Nivolumab, Pembrolizumab, Blinatumomab, Alemtuzumab, Evolocumab,Idarucizumab, Necitumumab, Dinutuximab, Secukinumab, Mepolizumab,Alirocumab, Daratumumab, Elotuzumab, Ixekizumab, Reslizumab, Olaratumab,Bezlotoxumab, Atezolizumab, Obiltoxaximab, Brodalumab, Dupilumab,Inotuzumab ozogamicin, Guselkumab, Sarilumab, Avelumab, Emicizumab,Ocrelizumab, Benralizumab, Durvalumab, Gemtuzumab ozogamicin, Erenumab,erenumab-aooe, Galcanezumab, galcanezumab-gnlm, Burosumab,burosumab-twza, Lanadelumab, lanadelumab-flyo, Mogamulizumab,mogamulizumab-kpkc, Tildrakizumab; tildrakizumab-asmn, Fremanezumab,fremanezumab-vfrm, Ravulizumab, ravulizumab-cwvz, Cemiplimab,cemiplimab-rwlc, Ibalizumab, ibalizumab-uiyk, Emapalumab,emapalumab-lzsg, Moxetumomab pasudotox, moxetumomab pasudotox-tdfk,Caplacizumab, caplacizumab-yhdp, Risankizumab, risankizumab-rzaa,Polatuzumab vedotin, polatuzumab vedotin-piiq, Romosozumab,romosozumab-aqqg, “Brolucizumab, brolucizumab-dbll”, Crizanlizumab;crizanlizumab-tmca, Enfortumab vedotin, enfortumab vedotin-ejfv,[fam-]trastuzumab deruxtecan, fam-trastuzumab deruxtecan-nxki,Teprotumumab, teprotumumab-trbw, Eptinezumab, eptinezumab-jjmr,Isatuximab, isatuximab-irfc, Sacituzumab govitecan; sacituzumabgovitecan-hziy, Inebilizumab, inebilizumab-cdon, “Tafasitamab,tafasitamab-cxix”, Belantamab mafodotin, belantamab mafodotin-blmf,Satralizumab, satralizumab-mwge, Atoltivimab, maftivimab, andodesivimab-ebgn, Naxitamab-gqgk, Margetuximab-cmkb, Ansuvimab-zykl,Evinacumab, Dostarlimab, dostarlimab-gxly, Loncastuximab tesirine,loncastuximab tesirine-lpyl, Tanezumab, Aducanumab, Tralokinumab,Teplizumab, Narsoplimab, Retifanlimab, Oportuzumab monatox, Anifrolumab,Inolimomb, Bimekizumab, Balstilimab, Sutimlimab (BIVV009), Ublituximab,Amivantamab, Tisotumab vedotin, Toripalimab, Omburtamab, or Balstilimab.In some embodiments, the antibody or antigen-binding fragment thereof isa multi-specific antibody (e.g., a bispecific antibody). In someembodiments, the antibody or antigen-binding fragment thereof is asingle-chain variable fragment (scFv). In some embodiments, the antibodyor antigen-binding fragment thereof is part of a chimeric antigenreceptor (CAR).

In some embodiments, the test compound is a small molecule drug. In someembodiments, the small molecule drug is designed for treating cancer.For example, the molecular target of the small molecule drug can beselected from tyrosine & serine/threonine kinases (e.g., Imanitib,Gefitinib, Erlotinib, Sunitinib, Lapatinib, Nilotinib, Sorafenib,Temsirolimus, Everolimus, Pazopanib, Crizotinib, Ruxolitinib, Axitinib,Bosutinib, Cabozantinib, Ponatinib, Regorafenib, Ibrutinib, Trametinib,and Perifosine); proteasomes (e.g., Bortezomib and Carfilzomib); matrixmetalloproteinases and heat shock proteins (e.g., Batimastat,Ganetespib, and NVP-AUY922); and apoptosis (e.g., Obatoclax andNavitoclax). In some embodiments, the small molecule drug is selectedfrom Afatinib, Axitinib, Bosutinib, Cabozantinib, Certinib, Crizotinib,Dasatinib, Erlotinib, Gefitinib, Ibrutinib, Imatinib, Lapatinib,Linsitinib, Lenvatinib, Osimertinib, Pazopanib, Ponatinib, Regorafenib,Rucaparib, Ruxolitinib, Sunitinib, and Vandetanib. Details can be found,e.g., in Pathak, Akshat, et al. Vivechan International Journal ofResearch 9.1 (2018): 36, which is incorporated herein by reference inits entirety.

In some embodiments, the small molecule drug is used for treating breastcancer, e.g., Ribociclib (Kisqali), Alpelisib (Piqray), Abemaciclib(Verzenio), Talazoparib (Telzenna), Nertinib (Nerlynx), Palbociclib(Ibrance), Ixabepilone (Ixempra), Anastrazole (Arimidex), Lapatinib(Tykerb), Toremifene (Fareston), Letrozole (Femara), Raloxifene(Evista), Tamoxifen Oral Liquid (Soltamax), Exemestane (Aromasin),Testosterone Cypionate (Depo-Testosterone), Fluoxymesterone(Halotestine/Androxy), Fadrozole (Afema), Tamibarotene (Amnolake), andTestosterone Propionate. In some embodiments, the small molecule drug isused for treating leukemia cancer, e.g., Gilteritinib (Xospata),Venetoclax (Venclexta), Bosutinib (Bosulif), Nilotinib (Tasigna),Tretinoin (Vesanoid), Clofarabine (Clolar), Cytarabine/Daunorubicin(Vyxeos), Dasatinib (Sprycel), Ponatinib (Iclusig), Enasidenib (Idhifa),Ivosidenib (Tibsovo), Cladribine (Mavenclad/Leustatin), MercaptopurineOral Suspension (Purixan), Methotrexate Oral Solution (Xatmep),Pentostatin (Nipent), Arsenic Trioxide (Trisenox), Quizartinib(Vanflyta), Histamine Dihydrochloride Injection (Ceplene), Ubenimix(Bestatin), Omacetaxine Mepesuccinate (Synribo), and Radotinib (Supect).In some embodiments, the small molecule drug is used for treating lungcancer, e.g., Gefitinib (Irresa), Entrectinib (Rozlytrek), Osimertinib(Tagrisso), Erlotinib (Tarceva), Brigatinib (Alunbirg), Lorbrena(Lorlatinib), Vinorelbine (Navelbine), Zykadia (Certinib), Pemetrexed(Alimta), Alectinib (Alecensa), Xalkori (Crizotinib), Nintedanib (Ofev),Anlotinib (Focus V), Amrubicin (Calsed), and Icotinib (Conmana). In someembodiments, the small molecule drug is used for treating lymphomas,e.g., Copanlisib (Aliqopa), Methoxsalen Solution (Uvadex), Pralatrexate(Folotyn), Bexarotene Topical (Targretin Gel), Pixantrone (Pixuvri),Belinostat (Beleodaq), Zanubrutinib (Brukinsa), Vorinostat (Zolinza),Romidepsin (Istodax), Bexarotene (Targretin), and Mechlorethamine(Valchlor/Ledaga). In some embodiments, the small molecule drug is usedfor treating myeloma, e.g., Ixazomib (Ninlaro), Melphalan Intravenous(Evomela/Chemostat), Thalidomide (Thalomid), Selinexor (Xpovio),Panobinostat (Farydak), Bortezomib (Velcade), Pomalidomide (Pomalyst),and Dexamethasone High Dose (Neofordex).

In some embodiments, the small molecule drug is used for treatingprostate cancer, e.g., Xtandi (Enzalutamide), Apalutamide (Erleada),Ertafitinib (Balversa), Darolutamide (Nubeqa), Bicalutamide (Casodex),Nilutamide (Nilandron), Abiraterone (Zytiga), Xofigo (Radium Ra 223dichloride), and Pedeliporfin (Tookad). In some embodiments, the smallmolecule drug is used for treating gastric cancer, e.g., Avapritinib(Ayvakit), Rivoceranib (Aitan), Gimeracil/Oteracil/Tegafur(Teysuno/TS-1), and Eptaplatin/Heptaplatin. In some embodiments, thesmall molecular drug is used for treating cancer diagnosis, e.g.,Fluciclovine 18F (Axumin), Tc 99m Tilmanocept (Lymphoseek), Perflubutane(Sonazoid), Hexyl Aminolevulinate (Cysview), Fluorocholine 18F(IASOcholine/Pcolina), and Gadobuterol (Gadavist). In some embodiments,the small molecule drug is used for treating skin cancer, e.g.,Benimetinib (Mektovi), Cobimetinib (Cotellic), Sonidegib (Odomzo),Vismodegib (Erivedge), Imiquimod (Aldara/Zyclara), Amivolevulinic Acid(Ameluz), Methyl Aminolevulinate (Metvixia/Metvix PDT), and Vemurafenib(Zelboraf). In some embodiments, the small molecule drug is used fortreating pancreatic cancer, e.g., Irinotecan Liposome Injection(Onivyde). In some embodiments, the small molecule drug is used fortreating thyroid tumors, e.g., Vendetanib (Caprelsa). In someembodiments, the small molecule drug is used for treating renal cancer,e.g., Axitinib (Inlyta). In some embodiments, the small molecule drug isused for treating colorectal cancer, e.g., Tipiracil/Trifluridine(Lonsurf), Irinotecan (Camptosar), Oxaliplatin (Eloxatin), Raltitrexed(Tomudex), Irinotecan-Eluting Beads (Paragon Beads/Debiri), andFruquintinib (Elunate). In some embodiments, the small molecule drug isused for treating solid tumors, e.g., Larotectinib (Viktravi). In someembodiments, the small molecule drug targets multiple cancers, e.g.,Fludarabin (Fludara/Oforta), Gemcitabine (Gemzar), Sorafnib (Nexavar),Rucaparib (Rubraca), Doxorubicin (Aridamycin), Acalabrutinib(Calquence), Ibrutinib (Imbruvica), Azacitidine (Vidaza), Lenalidomide(Revlimid), Doxorubicin Liposomal (Doxil), Tazemetostat (Tazverik),Busulfan (Busulfex), Afatinib (Gilotrif), Gemcitabine (Infugem),Carmustine Polifeprosan 20 wafer (Gliadel), Eribulin (Halaven),Paclitaxel-Protein Bound (Abraxane), Trabectedine (Yondelis), Paclitaxel(Taxol), Docetaxel (Taxotere), Idelalisib (Zydelig), Duvelisib(Copiktra), Regorafenib (Stivagra), Nelarabine (Arranon), Capecitabine(Xeloda), Lenvatinib (Lenvima), Olaparib (Lynparza), Niraparib (Zejula),Pazopanib (Votrient), Alitretinoin Topical (Panretin), Mitotane(Lysodren), Valrubicin (Valstar), Hydroxyurea (Hydrea), Mitoxantrone(Novantrone), Zoledronic Acid (Zometa/Reclast), Fotemustine (Muforan),Paclitaxel Nanoparticle (Nanoxel), Topotecan (Hycamtin), Decitabine(Decogen), Tivozanib (Fotivda), Telotristat Etiprate (Xermelo), Imatinib(Gleevec), Trametinib (Mekinist), Cabozantinib (Cabometyx), Encorafenib(Braftovi), Dabrafenib (Tafinlar), Sunintab (Sutent), Levoleucovorin(Fusilev/Khapzory), Bendamustine (Treanda/Belrapzo/Bendeka), Forodesine(Fodosine/Mundesine), Talaporfin (Laserphyrin), Tucidinostat (Epidaza),Doxorubicin Eluting Beads (DC Beads), Temozolomide (Temodar), PaclitaxelPolymeric Micelle Formulation (GenexolPM), Docetaxel polymeric micelle(Nanoxel M), Methotrexate, Treosulfan (Ovastat/Tercondi), Belotecan(Camtobell), Paclitaxel Liposomal(Lipusu/Bevetex), Amsacrine (AmsaPD/Amekrin), Cyclophosphamide, Docetaxel Nanosome (DoceAqualip),Pamidronic acid (Aredia), Mopidamol (Rapenton), Nedaplatin (Aqupla),Cytarabin/Cytarabin Liposomal (DepoCyt), and Dianhydrogalactitol (DAGfor Injection).

In some embodiments, the anti-cancer drug is a chemotherapy, e.g.,campothecin, doxorubicin, cisplatin, carboplatin, procarbazine,mechlorethamine, cyclophosphamide, adriamycin, ifosfamide, melphalan,chlorambucil, bisulfan, nitrosurea, dactinomycin, daunorubicin,bleomycin, plicomycin, mitomycin, etoposide, verampil, podophyllotoxin,tamoxifen, taxol, transplatinum, 5-flurouracil, vincristin, vinblastin,and/or methotrexate.

In some embodiments, the test compound is an anti-viral drug, e.g.,Acyclovir, Brivudin, Cidofovir, Famciclovir, Fomivirsen, Foscarnet,Ganciclovir, Penciclovir, Valacyclovir, Valganciclovir, Vidarabine,Amantadine, Rimantadine, Oseltamivir, Zanamivir, Interferons, Ribavirin,Adefovir, Emtricitabine, Entecavir, Lamivudine, Telbivudine, Tenofovir,Boceprevir, or Telaprevir. Details of anti-viral drugs can be found,e.g., in Razonable, R. R. Mayo Clinic Proceedings. Vol. 86. No. 10.Elsevier, 2011; De Clercq, E., et al., Clinical Microbiology Reviews29.3 (2016): 695-747; and De Clercq, E. Annual Review of Pharmacologyand Toxicology 51 (2011): 1-24; each of which is incorporated herein byreference in its entirety.

While not intending to be bound by any theory, it is believed that thetest compound described herein can be any molecule having desiredfunctions (e.g., anti-cancer functions) or functions to be determined.In some embodiments, when the test compound is applied to a biologicalsample, the cellular activity (e.g., any of the cellular activitiesdescribed herein) and/or gene expression (e.g., any of the geneexpression detections described herein) of the biological sample arechanged.

Also included herein are methods for screening test compounds, e.g.,polypeptides, polynucleotides, inorganic or organic large or smallmolecule test compounds, to identify agents useful in the treatment ofdisorders or diseases.

As used herein, “small molecules” refer to small organic or inorganicmolecules of molecular weight below about 3,000 Daltons. In general,small molecules useful for the invention have a molecular weight of lessthan 3,000 Daltons (Da). The small molecules can be, e.g., from at leastabout 100 Da to about 3,000 Da (e.g., between about 100 to about 3,000Da, about 100 to about 2500 Da, about 100 to about 2,000 Da, about 100to about 1,750 Da, about 100 to about 1,500 Da, about 100 to about 1,250Da, about 100 to about 1,000 Da, about 100 to about 750 Da, about 100 toabout 500 Da, about 200 to about 1500, about 500 to about 1000, about300 to about 1000 Da, or about 100 to about 250 Da).

The test compounds can be, e.g., natural products or members of acombinatorial chemistry library. A set of diverse molecules should beused to cover a variety of functions such as charge, aromaticity,hydrogen bonding, flexibility, size, length of side chain,hydrophobicity, and rigidity. Combinatorial techniques suitable forsynthesizing small molecules are known in the art, e.g., as exemplifiedby Obrecht and Villalgordo, Solid-Supported Combinatorial and ParallelSynthesis of Small-Molecular-Weight Compound Libraries,Pergamon-Elsevier Science Limited (1998), and include those such as the“split and pool” or “parallel” synthesis techniques, solid-phase andsolution-phase techniques, and encoding techniques (See, for example,Czarnik, Curr. Opin. Chem. Bio. 1:60-6 (1997)). In addition, a number ofsmall molecule libraries are commercially available. A number ofsuitable small molecule test compounds are listed in U.S. Pat. No.6,503,713, which is incorporated herein by reference in its entirety.

Libraries screened using the methods of the present invention cancomprise a variety of types of test compounds. A given library cancomprise a set of structurally related or unrelated test compounds. Insome embodiments, the test compounds are peptide or peptidomimeticmolecules. In some embodiments, the test compounds are nucleic acids.

In some embodiments, the test compounds and libraries thereof can beobtained by systematically altering the structure of a first testcompound, e.g., a first test compound that is structurally similar to aknown natural binding partner of the target polypeptide, or a firstsmall molecule identified as capable of binding the target polypeptide,e.g., using methods known in the art or the methods described herein,and correlating that structure to a resulting biological activity, e.g.,a structure-activity relationship study. As one of skill in the art willappreciate, there are a variety of standard methods for creating such astructure-activity relationship. Thus, in some instances, the work maybe largely empirical, and in others, the three-dimensional structure ofan endogenous polypeptide or portion thereof can be used as a startingpoint for the rational design of a small molecule compound or compounds.For example, in one embodiment, a general library of small molecules isscreened, e.g., using the methods described herein.

In some embodiments, a test compound is applied to a test sample, e.g.,a cell or living tissue, and one or more effects of the test compound isevaluated.

In some embodiments, the test sample is, or is derived from (e.g., asample taken from) an in vivo model of a disorder as described herein.For example, an animal model, e.g., a rodent such as a rat, can be used.

Methods for evaluating each of these effects are known in the art. Forexample, ability to modulate expression of a protein can be evaluated atthe gene or protein level, e.g., using quantitative PCR or immunoassaymethods. In some embodiments, high throughput methods, e.g., protein orgene chips as are known in the art (see, e.g., Ch. 12, Genomics, inGriffiths et al., Eds. Modern Genetic Analysis, 1999, W. H. Freeman andCompany; Ekins and Chu, Trends in Biotechnology, 1999, 17:217-218;MacBeath and Schreiber, Science 2000, 289(5485):1760-1763; Simpson,Proteins and Proteomics: A Laboratory Manual, Cold Spring HarborLaboratory Press; 2002; Hardiman, Microarrays Methods and Applications:Nuts & Bolts, DNA Press, 2003).

A test compound that has been screened by a method described herein anddetermined to be effective, can be considered a candidate compound. Acandidate compound that has been screened, e.g., in an in vivo model ofa disorder, and determined to have a desirable effect on the disorder,e.g., on one or more symptoms of the disorder, can be considered acandidate therapeutic agent. Candidate therapeutic agents, once screenedin a clinical setting, are therapeutic agents. Candidate compounds,candidate therapeutic agents, and therapeutic agents can be optionallyoptimized and/or derivatized, and formulated with physiologicallyacceptable excipients to form pharmaceutical compositions.

Thus, test compounds identified as “hits” (e.g., test compounds thatactivate or inhibit one or more cellular activities; alternatively, testcompounds that increase or decrease intracellular gene expression of anucleic acid) in a first screen can be selected and systematicallyaltered, e.g., using rational design, to optimize binding affinity,avidity, specificity, or other parameters. Such optimization can also bescreened for using the methods described herein. Thus, in oneembodiment, the invention includes screening a first library ofcompounds using a method known in the art and/or described herein,identifying one or more hits in that library, subjecting those hits tosystematic structural alteration to create a second library of compoundsstructurally related to the hit, and screening the second library usingthe methods described herein.

Test compounds identified as hits can be considered candidatetherapeutic compounds, useful in treating disorders or diseasesdescribed herein. A variety of techniques useful for determining thestructures of “hits” can be used in the methods described herein, e.g.,NMR, mass spectrometry, gas chromatography equipped with electroncapture detectors, fluorescence and absorption spectroscopy. Thus, thedisclosure also includes compounds identified as “hits” by the methodsdescribed herein, and methods for their administration and use in thetreatment, prevention, or delay of development or progression of adisorder described herein.

Test compounds identified as candidate therapeutic compounds can befurther screened by administration to a subject (e.g., an animal model)of a disorder or disease as described herein. The animal can bemonitored for a change in the disorder, e.g., for an improvement in aparameter of the disorder, e.g., a parameter related to clinicaloutcome. In some embodiments, the subject is a human.

In some embodiments, the methods described herein can be used to examinereal-time pharmacological and/or stimulus-dependent response of thebiological sample. In some embodiments, the methods described herein canexamine the pharmacological impact on gene expression. In someembodiments, the methods described herein can be used in conjunctionwith activity-based fluorescent reporters (e.g., calcium probes andvoltage-gated probes).

In some embodiments, the biological sample described herein is treatedwith one or more test compounds (e.g., drugs) before recording thecellular activity and/or the intracellular gene expression as describedherein. In some embodiments, the biological sample described herein istreated with one or more test compounds (e.g., drugs) at substantiallythe same time as recording the cellular activity and/or theintracellular gene expression as described herein.

In some embodiments, the test compound is conjugated with a fluorophore.In some embodiments, the test compound is conjugated with anoligonucleotide. In some embodiments, the oligonucleotide comprises asequence that uniquely identifies the test compound. In some instances,the biological sample can be treated with two or more test compounds,and each test compound is conjugated with a barcode sequence thatuniquely identifies the test compound. Details can be found, e.g., inU.S. Patent Application No. 62/963,897, which is incorporated herein byreference in its entirety.

In some embodiments, the temporal measurement results (e.g., thecellular activity or gene expression recordings) can be combined withthe spatial gene expression analysis results to provide spatio-temporalinsights in the biological sample (e.g., in response to drug treatment).In some embodiments, the spatio-temporal insights provide comprehensiveassessment of drug effects.

(h) Diffusion-Resistant Media/Lids

To increase efficiency by encouraging analyte diffusion toward thespatially-barcoded capture probes, a diffusion-resistant medium can beused. In general, molecular diffusion of biological analytes can occurin all directions, including toward the capture probes (i.e., toward thespatially-barcoded array), and away from the capture probes (i.e., intothe bulk solution). Increasing analyte migration toward thespatially-barcoded array reduces analyte diffusion away from thespatially-barcoded array and increases the capturing efficiency of thecapture probes, thereby increasing resolution of the spatial array.

In some embodiments, a diffusion-resistant medium is placed on top of abiological sample (e.g., the live tissue sample or cell sample describedherein) that is placed or cultured on top of a spatially-barcodedsubstrate. For example, the diffusion-resistant medium can be placedonto an array that a biological sample has been cultured on top. In someembodiments, the diffusion-resistant medium and spatially-barcoded arrayare the same component. For example, the diffusion-resistant medium cancontain spatially-barcoded capture probes within or on thediffusion-resistant medium (e.g., coverslip, slide, hydrogel, ormembrane). In some embodiments, a biological sample is placed orcultured on a substrate and a diffusion-resistant medium is placed ontop of the biological sample. Additionally, a spatially-barcoded captureprobe array can be placed in close proximity over a diffusion-resistantmedium. For example, a diffusion-resistant medium may be sandwichedbetween a spatially-barcoded array and a biological sample on asubstrate. In some embodiments, a diffusion-resistant medium is disposedor spotted onto a biological sample. In other embodiments, adiffusion-resistant medium is placed in close proximity to a biologicalsample.

In general, a diffusion-resistant medium can be any material known tolimit diffusivity of biological analytes. For example, adiffusion-resistant medium can be a solid lid (e.g., coverslip or glassslide). In some embodiments, a diffusion-resistant medium may be made ofglass, silicon, paper, hydrogel polymer monoliths, or other material. Insome embodiments, the glass slide can be an acrylated glass slide. Insome embodiments, the diffusion-resistant medium is a porous membrane.In some embodiments, the material may be naturally porous. In someembodiments, the material may have pores or wells etched into solidmaterial. In some embodiments, the pore volume can be manipulated tominimize loss of target analytes. In some embodiments, the membranechemistry can be manipulated to minimize loss of target analytes. Insome embodiments, the diffusion-resistant medium (e.g., hydrogel) isattached to a substrate (e.g., glass slide), for example by covalent ornon-covalent means. In some embodiments, a diffusion-resistant mediumcan be any material known to limit diffusivity of poly(A) transcripts.In some embodiments, a diffusion-resistant medium can be any materialknown to limit the diffusivity of proteins. In some embodiments, adiffusion-resistant medium can be any material know to limit thediffusivity of macromolecular constituents.

In some embodiments, a diffusion-resistant medium includes one or morediffusion-resistant media. For example, one or more diffusion-resistantmedia can be combined in a variety of ways prior to placing the media incontact with a biological sample including, without limitation, coating,layering, or spotting. As another example, a hydrogel can be placed ontoa biological sample followed by placement of a lid (e.g., glass slide)on top of the hydrogel.

In some embodiments, a force (e.g., hydrodynamic pressure, ultrasonicvibration, solute contrasts, microwave radiation, vascular circulation,or other electrical, mechanical, magnetic, centrifugal, and/or thermalforces) is applied to control diffusion and enhance analyte capture. Insome embodiments, one or more forces and one or more diffusion-resistantmedia are used to control diffusion and enhance capture. For example, acentrifugal force and a glass slide can used contemporaneously. Any of avariety of combinations of a force and a diffusion-resistant medium canbe used to control or mitigate diffusion and enhance analyte capture.

In some embodiments, a diffusion-resistant medium, along with thespatially-barcoded array and biological sample, is submerged in a bulksolution. In some embodiments, a bulk solution includes permeabilizationreagents. In some embodiments, a diffusion-resistant medium includes atleast one permeabilization reagent. In some embodiments, adiffusion-resistant medium (i.e. hydrogel) is soaked in permeabilizationreagents before contacting the diffusion-resistant medium to the sample.In some embodiments, a diffusion-resistant medium can include wells(e.g., micro-, nano-, or picowells) containing a permeabilization bufferor reagents. In some embodiments, a diffusion-resistant medium caninclude permeabilization reagents. In some embodiments, adiffusion-resistant medium can contain dried reagents or monomers todeliver permeabilization reagents when the diffusion-resistant medium isapplied to a biological sample. In some embodiments, adiffusion-resistant medium is added to the spatially-barcoded array andsample assembly before the assembly is submerged in a bulk solution. Insome embodiments, a diffusion-resistant medium is added to thespatially-barcoded array and sample assembly after the sample has beenexposed to permeabilization reagents. In some embodiments,permeabilization reagents are flowed through a microfluidic chamber orchannel over the diffusion-resistant medium. In some embodiments, theflow controls the sample's access to the permeabilization reagents. Insome embodiments, target analytes diffuse out of the sample and toward abulk solution and get embedded in a spatially-barcoded captureprobe-embedded diffusion-resistant medium. In some embodiments, a freesolution is sandwiched between the biological sample and adiffusion-resistant medium.

FIG. 7 is an illustration of an exemplary use of a diffusion-resistantmedium. A diffusion-resistant medium/lid 702 can be contacted with asample 703. In FIG. 7, a glass slide 704 is populated withspatially-barcoded capture probes 706, and the sample 703, is contactedwith the array 704 and spatially-barcoded capture probes 706. Adiffusion-resistant medium/lid 702 can be applied to the sample 703,wherein the sample 703 is sandwiched between a diffusion-resistantmedium 702 and a capture probe coated slide 704. When a permeabilizationsolution 701 is applied to the sample, using the diffusion-resistantmedium/lid 702 directs migration of the analytes 705 toward the captureprobes 706 by reducing diffusion of the analytes out into the medium.Alternatively, the diffusion resistant medium/lid may containpermeabilization reagents.

(i) Electrophoretic Transfer

In some embodiments, electrophoretic transfer of analytes can beperformed while retaining the relative spatial locations of analytes ina biological sample while minimizing passive diffusion of an analyteaway from its location in a biological sample. In some embodiments, ananalyte captured by a capture probe (e.g., capture probes on asubstrate) retains the spatial location of the analyte present in thebiological sample from which it was obtained (e.g., the spatial locationof the analyte that is captured by a capture probe on a substrate whenthe analyte is actively migrated to the capture probe by electrophoretictransfer can be more precise or representative of the spatial locationof the analyte in the biological sample than when the analyte is notactively migrated to the capture probe). In some embodiments,electrophoretic transport and binding process is described by theDamköhler number (Da), which is a ratio of reaction and mass transportrates. The fraction of analytes bound and the shape of the biologicalsample will depend on the parameters in the Da. There parameters includeelectromigration velocity U_(e)(depending on analyte electrophoreticmobility μ_(e) and electric field strength E), density of capture probes(e.g., barcoded oligonucleotides) p₀, the binding rate between probes(e.g., barcoded oligonucleotides) and analytes k_(on), and capture areathickness L.

${Da} \sim \frac{k_{on}p_{0}L}{\mu_{e}E}$

Fast migration (e.g., electromigration) can reduce assay time and canminimize molecular diffusion of analytes.

In some embodiments, electrophoretic transfer of analytes can beperformed while retaining the relative spatial alignment of the analytesin the sample. As such, an analyte captured by the capture probes (e.g.,capture probes on a substrate) retains the spatial information of thecell or the biological sample from which it was obtained. Applying anelectrophoretic field to analytes can also result in an increase intemperature (e.g., heat). In some embodiments, the increased temperature(e.g., heat) can facilitate the migration of the analytes towards acapture probe.

In some examples, a spatially-addressable microelectrode array is usedfor spatially-constrained capture of at least one charged analyte ofinterest by a capture probe. For example, a spatially-addressablemicroelectrode array can allow for discrete (e.g., localized)application of an electric field rather than a uniform electric field.The spatially-addressable microelectrode array can be independentlyaddressable. In some embodiments, the electric field can be applied toone or more regions of interest in a biological sample. The electrodesmay be adjacent to each other or distant from each other. Themicroelectrode array can be configured to include a high density ofdiscrete sites having a small area for applying an electric field topromote the migration of charged analyte(s) of interest. For example,electrophoretic capture can be performed on a region of interest using aspatially-addressable microelectrode array.

A high density of discrete sites on a microelectrode array can be used.The surface can include any suitable density of discrete sites (e.g., adensity suitable for processing the sample on the conductive substratein a given amount of time). In one embodiment, the surface has a densityof discrete sites greater than or equal to about 500 sites per 1 mm². Insome embodiments, the surface has a density of discrete sites of about100, about 200, about 300, about 400, about 500, about 600, about 700,about 800, about 900, about 1,000, about 2,000, about 3,000, about4,000, about 5,000, about 6,000, about 7,000, about 8,000, about 9,000,about 10,000, about 20,000, about 40,000, about 60,000, about 80,000,about 100,000, or about 500,000 sites per 1 mm². In some embodiments,the surface has a density of discrete sites of at least about 200, atleast about 300, at least about 400, at least about 500, at least about600, at least about 700, at least about 800, at least about 900, atleast about 1,000, at least about 2,000, at least about 3,000, at leastabout 4,000, at least about 5,000, at least about 6,000, at least about7,000, at least about 8,000, at least about 9,000, at least about10,000, at least about 20,000, at least about 40,000, at least about60,000, at least about 80,000, at least about 100,000, or at least about500,000 sites per 1 mm².

Schematics illustrating an electrophoretic transfer system configured todirect nucleic acid analytes (e.g., mRNA transcripts) toward aspatially-barcoded capture probe array are shown in FIG. 8A and FIG. 8B.In this exemplary configuration of an electrophoretic system, a sample802 is sandwiched between the cathode 801 and the spatially-barcodedcapture probe array 804, 805, and the spatially-barcoded capture probearray 804, 805 is sandwiched between the sample 802 and the anode 803,such that the sample 802, 806 is in contact with the spatially-barcodedcapture probes 807. When an electric field is applied to theelectrophoretic transfer system, negatively charged nucleic acidanalytes 806 will be pulled toward the positively charged anode 803 andinto the spatially-barcoded array 804, 805 containing thespatially-barcoded capture probes 807. The spatially-barcoded captureprobes 807 interact with the nucleic acid analytes (e.g., mRNAtranscripts hybridize to spatially-barcoded nucleic acid capture probesforming DNA/RNA hybrids) 806, making the analyte capture more efficient.The electrophoretic system set-up may change depending on the targetanalyte. For example, proteins may be positive, negative, neutral, orpolar depending on the protein as well as other factors (e.g.,isoelectric point, solubility, etc.). The skilled practitioner has theknowledge and experience to arrange the electrophoretic transfer systemto facilitate capture of a particular target analyte.

FIGS. 9A-9G is an illustration showing an exemplary workflow protocolutilizing an electrophoretic transfer system. In the example, FIG. 9Adepicts a flexible spatially-barcoded feature array being contacted witha sample. The feature array can be a flexible array, wherein the sampleis immobilized on a hydrogel, membrane, or other substrate. FIG. 9Bdepicts contact of the array with the sample and imaging of thearray-sample assembly. The image of the sample/array assembly can beused to verify sample placement, choose a region of interest, or anyother reason for imaging a sample on an array as described herein. FIG.9C depicts application of an electric field using an electrophoretictransfer system to aid in proximal capture of a target analyte by thecapture probes on the array. Here, negatively charged mRNA targetanalytes migrate toward the positively charged anode. FIG. 9D depictsapplication of reverse transcription reagents and first strand cDNAsynthesis of the captured target analytes. FIG. 9E depicts array removaland preparation for library construction (FIG. 9F) and next-generationsequencing (FIG. 9G).

(o) Kits

In some embodiments, also provided herein are kits that include one ormore reagents to detect one or more analytes described herein. In someinstances, the kit includes a substrate comprising a plurality ofcapture probes comprising a spatial barcode and the capture domain. Insome instances, the kit includes any of the apparatus or componentsthereof as described herein.

A non-limiting example of a kit used to perform any of the methodsdescribed herein includes: a) an array comprising a plurality of captureprobes; b) a perfusion chamber defined by mounting a gasket on thearray, and a cover mounted on the gasket, wherein the cover includes:(i) an inlet being fluidly connected to a plurality of input channels,and (ii) an outlet being fluidly connected to a plurality of outputchannels; and c) an instruction for using the kit.

A non-limiting example of a kit used to perform any of the methodsdescribed herein includes: a) a multi-well plate comprising a pluralityof capture probes, wherein the plurality of capture probes are directlyattached (e.g., printed) to a surface of a well of the multi-well plate;and b) an instruction for using the kit. Another non-limiting example ofa kit used to perform any of the methods described herein includes: a) acoverslip comprising a plurality of capture probes; b) a multi-wellplate, wherein the coverslip is attached to a surface of a well of themulti-well plate; and c) an instruction for using the kit. In someembodiments, the multi-well plate is a 6-well plate, an 8-well plate, a12-well plate, a 24-well plate, a 48-well plate, or a 96-well plate.

A non-limiting example of a kit used to perform any of the methodsdescribed herein includes: a) a slide comprising a plurality of arrays,wherein an array of the plurality of arrays comprises capture probes; b)a gasket comprising a plurality of apertures, wherein the gasket isconfigured to be mounted onto the slide such that the plurality ofapertures are aligned with the plurality of arrays; and c) aninstruction for using the kit.

EXAMPLES

The invention is further described in the following examples, which donot limit the scope of the invention described in the claims.

Example 1 Live Sample Preparation and System Setup

Live samples can be prepared for spatio-temporal measurements as shownin FIGS. 12A-12D. Live samples (e.g., live tissue sections) can begenerated using a Vibratome (FIG. 12A) and viability maintained (FIG.12B) in oxygenated media. Traditional chambers equipped with an inletand outlet port for constant flow of media can be designed to promotelaminar flow as exemplified in FIG. 12C. Such chambers can be adapted toassemble with the spatial array described herein. Alternatively,perfusion chamber assembly can be custom made, for example, as shown inFIGS. 10A-10B. Testing can occur by, for example, placing the perfusionchamber under a microscope or other device or apparatus for capturingcellular activity or gene expression upon testing of the live sample(FIG. 12D).

Example 2 Measuring Cellular Activity using the Perfusion Chamber or theMulti-Well Plate

As a non-limiting example, the perfusion chamber or the multi-well platedescribed herein can be used for measurement of cellular activity. Forexample, live brain tissue sample can be sectioned from a fresh braintissue by Vibratome and cultured in a perfusion chamber or a multi-wellplate described here. Tissue culture medium specific for live brainsamples can be perfused through (or added by pipetting) to maintaintissue viability. Voltage-sensitive dyes can be added to the culturemedium and perfused to the perfusion chamber (or added to the multi-wellplate by pipetting) to interact with the brain tissue sample. Fastmembrane potential changes, e.g., action potentials in single neurons,can be optically recorded by time-lapse fluorescent microscopy.Immediately following the recording, the brain tissue sample can befixed by 2% paraformaldehyde. Following fixation, the cover and gasketare disassembled. The tissue sample can then be subjected to a spatialanalysis workflow as described herein.

Example 3 Measuring Intracellular Gene Expression using the PerfusionChamber or the Multi-Well Plate

As a non-limiting example, a perfusion chamber (or a multi-well plate)described herein can be used for measurement of intracellular geneexpression, e.g., splicing of a transcript by FRET. For example, cellsexpressing the gene transcript can be seeded directly in the perfusionchamber (or the multi-well plate) and cultured for at least 2 days whencell confluence reaches about 80%. Two fluorescently labelled PNA probescan be perfused to the perfusion chamber (or added to the multi-wellplate by pipetting) to interact with the cells. The first probetargeting to an upstream exon can be labelled with Cyan FluorescentProtein (CFP) and the second probe targeting to a downstream exon can belabelled with Venus Fluorescent Protein (VFP or Venus). Upon splicing,the ligated upstream and downstream exons are close enough (e.g., within10 nm) such that emission of CFP can excite VFP, resulting inVFP-specific fluorescence emission signals. Drugs that interfere withsplicing can also be perfused (or added by pipetting) to interact withthe cells and VFP-specific emission signals can be recorded. Immediatelyfollowing the recording, the cells can be fixed by 2% paraformaldehyde.Following fixation, the cover and gasket are disassembled. The cellsample can then be subjected to a spatial analysis workflow as describedherein.

As a non-limiting example, the perfusion chamber or the multi-well platedescribed herein can be used for measurement of intracellular geneexpression, e.g., visualizing transcripts in live cells or tissues. Livecells expressing a target mRNA sequence can be seeded directly in theperfusion chamber (or the multi-well plate) and cultured when celldensity reaches an appropriate confluence. As shown in FIGS. 13A-13C andFIG. 14, two fluorescently labeled oligo probes (oligo probe A and oligoprobe B) targeting neighboring sequences of the target mRNA can be addedto the perfusion chamber (or the multi-well plate) to internalize intothe live cells. Oligo probe A can be labelled with a CFP as a donorfluorophore and oligo probe B can be labelled with VFP (or Venus) as anacceptor fluorophore. FRET can occur when emission spectra from thedonor fluorophore overlaps with the excitation spectra of the acceptorfluorophore. FRET can be detected when distance of the donor andacceptor fluorophores are less than 10 nm and both fluorophores arecorrectly orientated. Specifically, CFP from oligo probe A can beexcited at 405 nm and emits at 477 nm. When VFP from oligo probe B is ata distance less than 10 nm to CFP, the 477 nm emission can furtherexcite VFP to emit at 528 nm. FIG. 15 shows an exemplary recordingresult of the emission at 477 nm and 528 nm when the cells are excitedat 405 nm for a period of time. When the target mRNA is expressed, thetwo oligo probes can hybridize to the neighboring sequences of thetarget mRNA that allows FRET to occur, which is indicated as a decreaseof the 477 emission signal with a simultaneous increase of the 528emission signal. When the target mRNA is degraded, the free diffusingoligo probes would have a reduced rate of FRET occurrence, which isindicated as an increase of the 477 nm emission signal with asimultaneous decrease of the 528 nm emission signal. In addition, asshown in FIG. 16, drugs that interfere with the target mRNA expressioncan also trigger the 477 nm and 528 nm emission signal response duringdrug treatment. Immediately following the recording, the live cells canbe washed and perfused (or added by pipetting) with fixatives (e.g., 2%paraformaldehyde). Alternatively, snap-shots of the live cells afterdrug treatments can be obtained by perfusing (or adding) the fixativesat different time points with proper controls (e.g., no treatmentcontrols). Following fixation, the cover and gasket are disassembled.The cell sample can then be subjected to a spatial analysis workflow asdescribed herein.

Example 4 Drug Screening using the Perfusion Chamber or the Multi-WellPlate

As a non-limiting example, the perfusion chamber or the multi-well platedescribed herein can be used for drug screening. As shown in FIG. 19,skin or blood cells from human patients having a specific disease can becollected to generate patient-specific induced pluripotent stem cells(iPS cells). The iPS cells can be cultured in a dish to mimicdisease-affected cells. Alternatively, the iPS cells can be stimulatedto differentiate into an organoid sample, which can be used as a diseasemodel. The organoid sample can be dissected and transferred into theperfusion chamber or the multi-well plate as described herein.Afterwards, the test compounds (e.g., drugs) can be diluted and used totreat the organoid sample in each chamber (or well) with propercontrols. Cellular activities and/or intracellular gene expressions canbe detected (e.g., recorded) in response to test compounds (e.g., drugs)treatment. The organoid sample can then be subjected to a spatialanalysis workflow as described herein. Based on changes of the detectedcellular activities and/or the intracellular gene expressions, togetherwith the spatial analysis results, disease-specific drugs can bedetermined and used to treat the specific disease in the human patients.

Example 5 Tissue Culture on Spatial Arrays

Feasibility of cell culture on spatial arrays was assessed, according tothe Visium Tissue Optimization Protocol. Specifically, A549 (ATCC®CCL-185™) human epithelial lung carcinoma cells were cultured in a T75flask using F-12K media (ATCC® 30-2004) supplemented with 10% fetalbovine serum (FBS; ATCC® 30-2020). The cells were harvested whenconfluence reached 80-90%. Specifically, the cells were washed 1× withphosphate buffered saline (PBS; no Mg²⁺, no Ca²⁺), and dissociated in 3ml of 0.25% (w/v) trypsin supplemented with 0.53 mMethylenediaminetetraacetic acid (EDTA) for 5 minutes at 37° C. Afterdissociation, 3 ml of warmed complete media (F-12K, 10% FBS) was addedand the cells were gently mixed by pipetting. The cells were transferredto a 15 ml Falcon tube, followed by centrifugation at 300 g for 15minutes. After centrifugation, the supernatant was discarded and thecell pellet was resuspended with 1 ml of complete media. The totalnumber of cells was counted using a Countess™ II automated cell counter(Thermo Fisher Scientific) after staining with 0.04% trypan blue dye.After determination of cell concentration, the cells were diluted to20,000 cells per 200 μl, and 200 μl of the diluted cell suspension wasadded to each well of an assembled cassette. The assembled cassetteincluded a spatial array slide that was assembled into a slide cassettevia a removable gasket (details can be found in the Visium SpatialTissue Optimization Reagent Kits User Guide (e.g., Rev D, dated October2020), which is available at the 10x Genomics Support Documentationwebsite). The assembled cassette was placed in a secondary container,and the cells were cultured until confluence reached 80-90%. The culturemedia was aspirated, and the cells were fixed in 4% paraformaldehyde(PFA). The fixed cells were stained and imaged. Analysis was performedaccording to the Visium Tissue Optimization Protocol. In particular,cDNA footprint images were obtained following tissue removal, with thecell outlines representing the collected mRNA from the A549 cells.

FIGS. 20A-20C, show the merged cell image and cDNA footprint image. ThecDNA footprint image overlaid and aligned with the stained A549 cellimage on the array slide. In general, the cDNA footprint followed theshape and morphology of the individual cells. However, transcriptmislocalization (or transcript diffusion) was also observed, which ledto a visible halo of transcripts surrounding the individual cells. It iscontemplated that the addition of agents, such as crowding agents, wouldminimize the transcripts diffusing from the cells.

Feasibility of cell culture on spatial arrays was assessed, according tothe Visium Gene Expression Protocol. The cells were treated with smallmolecule drugs (i.e., Osimertinib or Linsitinib) before harvesting.Specifically, A549 cells were prepared and added to each well of anassembled cassette as described above. The assembled cassette included aspatial array slide that was assembled into a slide cassette via aremovable gasket (details can be found in the Visium Spatial GeneExpression Reagent Kits User Guide (e.g., Rev D, dated October 2020),which is available at the 10x Genomics Support Documentation website).The assembled cassette was placed in a secondary container, and thecells were cultured until confluence reached 80-90% (approx. 3 days).About 24 hours prior to harvesting, the cells were left untreated (as acontrol); treated with Osimertinib; treated with Linsitinib; or treatedwith both Osimertinib and Linsitinib. After harvesting, the culturemedia was aspirated, and the cells were fixed in 4% PFA. The fixed cellswere imaged by brightfield microscopy, and spatial gene expressionanalysis was performed according to the Visium Gene Expression Protocol,which included steps of library preparation, sequencing, and dataanalysis. Following treatment and processing, experimental data wasobtained from one replicate of untreated cultures, one replicate ofLinsitinib-treated cultures, and two replicates of Osimertinib-treatedcultures.

As shown in FIG. 21A, A549 cells were viable and proliferated on top ofthe spatial array slide. Cell images were taken by capturing theautofluorescence emitted from the cells, and the viable cells appearedmorphologically normal. Growth on or surrounding the printed fiducialswere also observed. FIG. 21B indicates that regions of higher celldensity coincided with higher relative UMI counts.

Spatial UMI counts and gene detection counts were determined inuntreated and drug-treated cultures. As shown in FIGS. 22A-22D,transcript capture was detected as indicated by spatial UMI and geneplots, indicating that culturing cells on top of the spatial array slidedid not affect data quality of the spatial analysis. However, it iscontemplated that one or both of non-uniform cell growth pattern andcell detachment during processing may have resulted in areas of low UMIand gene counts.

The spatial analysis results of the untreated and drug-treated cultureswere also compared. FIGS. 23A-23E showed that the sequencing metricsderived from each of cultured capture areas exhibited comparableresults. Because two replicates of Osimertinib-treated cells were usedin the analysis, it was contemplated that the Osimertinib-treated areaswould have an increased variation of sequencing saturation, median genesper cells, median counts per cell, and median UMIs per cell as comparedto untreated areas or Linsitinib-treated areas (FIGS. 23A-23D). Inaddition, the two replicates of Osimertinib-treated cells also accountedfor the clustering variation observed within the UMAP plot (FIG. 23E).Nevertheless, distinct clustering patterns were detected between theuntreated, Osimertinib-treated, and Linsitinib-treated cultures.

In addition, a differential analysis on gene expression based on theuntreated and drug-treated cultures were determined and the results areshown in FIGS. 24A-24B. The results showed that multiple genes weredifferentially expressed (e.g., either upregulated or downregulated)after treatment of Osimertinib or Linsitinib to the live cells. Forexample, as compared to the Linsitinib-treated cells,Osimertinib-treated cells exhibited increased expression of BMF, IGFBP1,CEMIP, PRRG3, and COL6A3; as compared to the untreated cells,Linsitinib-treated cells exhibited increased expression of SLC6A12,PRSS35, RAB17, AKR1B1, and IGFL2-AS1 (FIG. 24A). The top differentiallyexpressed genes were also detected. For example, as compared to theLinsitinib-treated cells, the top 5 genes with increased expressionlevel in Osimertinib-treated cells were PRRG3, CITED4, AHNAK2, NPDC1,and ITGA3; as compared to untreated cells, the top 5 genes withincreased expression level in Linsitinib-treated cells were PRSS35,AKR1B1, IGFL2-AS1, CCL2, and CRYAB (FIG. 24B).

Further, a meta-analysis was performed on the samples using theSingle-Cell Consensus Clustering Prime (SC3′ or SC3P) (details can befound in the Chromium Next GEM Single Cell 3′ Reagent Kits v3.1 (DualIndex) (e.g., Rev B, dated March 2021), which is available at the 10xGenomics Support Documentation website) or Visium pipelines, as shown inFIG. 25. Within the clustering results obtained by each tool, observableseparation of the clustering pattern of Osimertinib-treated cultures wasdetected from those of the untreated or Linsitinib-treated cultures.Thus, differential gene expression induced by drug treatment wasdemonstrated by treating living cells with different drugs andevaluating their effect on gene expression using either single cell orspatial analysis pipelines.

OTHER EMBODIMENTS

It is to be understood that while the invention has been described inconjunction with the detailed description thereof, the foregoingdescription is intended to illustrate and not limit the scope of theinvention, which is defined by the scope of the appended claims. Otheraspects, advantages, and modifications are within the scope of thefollowing claims.

1.-79. (canceled)
 80. A method for identifying location and abundance ofan analyte in a biological sample, the method comprising: (a) contactingthe biological sample with a substrate comprising a plurality of captureprobes, wherein a capture probe of the plurality of the capture probescomprises (i) a spatial barcode and (ii) a capture domain that bindsspecifically to a sequence present in the analyte; (b) recording acellular activity or an intracellular gene expression of a nucleic acidof the biological sample, wherein the biological sample is locatedwithin a perfusion chamber comprising a gasket and the substrate,wherein the gasket comprises (i) a plurality of apertures, (ii) aplurality of input channels being fluidly connected to the plurality ofapertures, respectively, and (iii) a plurality of output channels beingfluidly connected to the plurality of apertures, respectively; (c)hybridizing the analyte to the capture domain of the capture probe; (d)extending the capture probe using the analyte as a template, therebygenerating an extended capture probe; (e) amplifying the extendedcapture probe to produce a plurality of extended capture probes; and (f)determining (i) all or part of the sequence of the spatial barcode, or acomplement thereof, and (ii) all or part of the sequence of the analyte,or a complement thereof, and using the determined sequences of (i) and(ii) to identify the location and abundance of the analyte in thebiological sample.
 81. The method of claim 80, further comprisingmounting the gasket onto the substrate, wherein the substrate comprisesa plurality of substrate regions, wherein a substrate region of theplurality of substrate regions comprises the capture probe comprising(i) the spatial barcode and (ii) the capture domain that bindsspecifically to the sequence present in the analyte, and wherein theplurality of apertures of the gasket are aligned with the plurality ofsubstrate regions of the substrate when the gasket is mounted onto thesubstrate.
 82. The method of claim 81, further comprising mounting acover onto the gasket, wherein the cover comprises an inlet and anoutlet, the inlet being fluidly connected to the plurality of inputchannels when the cover is mounted onto the gasket, the outlet beingfluidly connected to the plurality of output channels when the cover ismounted onto the gasket, and wherein the perfusion chamber furthercomprises the cover that is mounted onto the gasket.
 83. The method ofclaim 80, further comprising perfusing a test compound through theperfusion chamber.
 84. The method of claim 83, wherein the test compoundis a drug.
 85. The method of claim 83, wherein the perfusing step occursprior to the recording step, or wherein the perfusing step and therecording step occur at substantially the same time.
 86. The method ofclaim 80, further comprising culturing the biological sample in theperfusion chamber before the recording step.
 87. The method of claim 86,wherein the biological sample is cultured in a culture medium in theperfusion chamber.
 88. The method of claim 87, wherein the culturemedium is supplemented with oxygen.
 89. The method of claim 87, whereinthe culture medium comprises a blocking reagent, or wherein thebiological sample is treated with the blocking reagent.
 90. The methodof claim 80, wherein the recording step comprises optical recording. 91.The method of claim 90, wherein the optical recording comprisescontacting the biological sample with a chemical dye or an indicator.92. The method of claim 91, wherein the chemical dye or the indicatorcomprises a fluorophore.
 93. The method of claim 90, wherein the opticalrecording is achieved by in situ hybridization or fluorescence resonanceenergy transfer (FRET).
 94. The method of claim 90, wherein the opticalrecording comprises hybridization of a plurality of optically-labelledprobes to (a) a protein, a lipid, a nucleic acid, or a combinationthereof associated with the cellular activity; or (b) the nucleic acidassociated with the intracellular gene expression.
 95. The method ofclaim 94, wherein an optically-labelled probe of the plurality ofoptically-labelled probes is a peptide nucleic acid (PNA) probe labelledwith a fluorophore.
 96. The method of claim 80, wherein the biologicalsample is a cell culture sample or a tissue sample.
 97. The method ofclaim 96, wherein the tissue sample is a live tissue section, anorganoid sample, or a spheroid culture sample.
 98. The method of claim96, wherein the cell culture sample is a primary cell culture samplecomprising cells from a fresh tissue.
 99. The method of claim 80,wherein the substrate is a coverslip comprising plastic, metal, orglass.
 100. The method of claim 80, wherein the biological samplecomprises a plurality of live cells, and the live cells are stained byimmunohistochemistry or immunofluorescence before the recording step.101. The method of claim 80, wherein the biological sample is stainedusing a detectable label, wherein the detectable label is Can-Grunwald,Giemsa, hematoxylin and eosin (H&E), Jenner's, Leishman, Masson'strichrome, Papanicolaou, Romanowsky, silver, Sudan, Wright's, orPeriodic Acid Schiff (PAS).
 102. The method of claim 80, wherein thebiological sample is imaged using bright field imaging.
 103. The methodof claim 80, wherein the biological sample is permeabilized with apermeabilization agent selected from an organic solvent, a cross-linkingagent, a detergent, and an enzyme, or a combination thereof.
 104. Themethod of claim 80, wherein the biological sample is fixed with ethanol,methanol, acetone, formaldehyde, paraformaldehyde-Triton,glutaraldehyde, or a combination thereof.
 105. The method of claim 80,wherein at the extending step, the capture probe is extended at the 3′end.
 106. The method of claim 80, wherein the biological sample isremoved after the amplifying step.
 107. The method of claim 80, whereinthe amplifying step comprises amplifying (i) all or part of sequence ofthe analyte bound to the capture domain, or a complement thereof, and(ii) all or a part of the sequence of the spatial barcode, or acomplement thereof.
 108. The method of claim 80, wherein the determiningstep comprises sequencing.
 109. The method of claim 80, wherein thedetermining step comprises sequencing (i) all or a portion of thesequence of the spatial barcode or the complement thereof, and (ii) allor a portion of the sequence of the analyte.